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Abstract 
 
IMOLA G. ZIGONEANU: α-Synuclein Interaction with Membranes 
(Under the direction of Professor Gary J. Pielak, Ph.D.) 
 
The association of α-synuclein with membranes appears to be an 
important factor in Parkinson’s disease. My dissertation research was focused on 
understanding the interactions of the protein with artificial membranes, the 
extracellular plasma membrane, and intracellular membranes. Fluorescence and 
nuclear magnetic resonance spectroscopy were used to monitor these 
interactions. Large unillamelar vesicles with a composition similar to 
mitochondrial membranes were studied. Cardiolipin, present mainly in the inner 
mitochondrial membrane, is key for protein binding, and reducing the amount of 
cardiolipin decreases binding. The nature of cardiolipin’s acyl chains is also 
important; cardiolipin with chains containing one double bond interact more 
strongly than those with chains having two double bonds or saturated acyl 
chains. This finding is physiologically relevant for Parkinson’s disease because 
cardiolipin containing fatty acids with one double bond are the most abundant 
phospholipid in the brain. The affinity of α-synuclein for plasma membrane was 
tested, and only N-terminal region of the protein binds. Also, 19F NMR proved 
useful for monitoring the interactions of proteins and fused peptide-proteins with 
the plasma membrane. Information on protein interactions with intracellular 
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membranes reveals that the N-terminal region may be cleaved in cells, but 
further studies are needed to confirm this idea.  
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CHAPTER 1 
Introduction 
 
Reproduced in part with permission from Biochemistry. Copyright 2009 American 
Chemical Society 
1.1 Parkinson’s Disease 
Parkinson’s disease is the second most common progressive neurological 
disorder [1, 2] affecting more than 500,000 people in United States with more 
than 50,000 new cases reported annually [3]. Its symptoms include rest tremor, 
bradykinesia, rigidity and loss of postural reflexes [4]. The disease is more 
prevalent in subjects older than 50, with the symptoms progressing more quickly 
in some individuals [3, 5].  
Parkinson’s disease is caused by the loss of dopaminergic neurons within 
the substantia nigra pars compacta [6-8]. The disease is also characterized by 
the presence of Lewy bodies in the cytoplasm of neurons in the substantia nigra. 
Lewy bodies are pathological inclusions of 5-25 µm in diameter [9] having α-
synuclein as a primary component [9-12]. Parkinson’s disease is diagnosed only 
based on clinical symptoms; no single laboratory test exists. The factors that are 
believed to cause the disease (because they induce Parkinson’s symptoms in
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animal models) are: environmental [13-18], genetic [19, 20], and age-related [5, 
21].  
1.2 α-Synuclein 
α-Synuclein is an intrinsically-disordered protein found in the presynaptic 
nerve terminals [22-28]. The 140-residue protein comprises a positively-charged 
N-terminus, a hydrophobic middle region, and a negatively charged C-terminus 
[29-31]. In its monomeric form, α-synuclein is natively unfolded but can assume a 
β-sheet character or α-helical structure depending on the solution conditions [32-
34]. Also, α-synuclein forms protofibrils [35, 36] and fibrils [37, 38] that are toxic 
for the neurons.  
The N-terminal region of α-synuclein forms an α-helix upon interaction 
with vesicles of different lipid composition [39], phospholipid headgroups [40], 
sizes [41], and surfaces [42, 43].  It is known that the protein has a higher affinity 
for small unilamellar vesicles than for large unilamellar vesicles (LUVs), and that 
the protein binds more strongly to vesicles containing anionic phospholipids [39, 
40, 44, 45]. 
Two α-synuclein variants, A30P and A53T, associated with Parkinson’s 
disease have been identified [46]. In vitro studies confirm that fibrils form at an 
increased rate for these mutants compared to wild-type α-synuclein, revealing 
the importance of these α-synuclein mutations in protein aggregation [6]. α-
Synuclein is suspected to have multiple functions including roles in 
neurotransmitter release [47], mitochondrial dysfunction [48-50], and aging [51].  
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A recent study shows that α-synuclein is implicated in SNARE-complex 
assembly at presynaptic vesicles via its C-terminal region  while its N-terminal 
region is anchored to the vesicle [47]. The protein is involved in synaptic activity 
when the nerve terminals repeatedly release neurotransmitters necessary for 
assembly and disassembly of the complex. However, another recent study, 
shows that α-synuclein isolated under non-denaturing conditions from brain 
tissue and human cells is a partly-folded tetramer that is more resistant to 
aggregation as compared to monomeric α-synuclein [52]. These recent findings 
are important to gain insight into α-synuclein intracellular functions and represent 
steps forward in elucidating the biochemistry of Parkinson’s disease. They also 
indicate that a complete understanding of α-synuclein structure and functions and 
how these properties relate to the disease need to be studied in the future.     
1.3 Delivery Systems  
Several peptides have been designed to cross the plasma membrane of 
different cell types. Among these, the PEP family of amphipathic carriers have 
been used to transport proteins and peptides [53, 54], antibodies [54], and 
nucleic acids [55-57] into higher eukaryotic cells. The main component of this 
class is the peptide, PEP-1 (Ac-KETWWETWWTEWSQPKKKRKV-Cya). This 
peptide comprises a hydrophobic tryptophan-rich domain that interacts with the 
cargo, a hydrophilic lysine-rich domain designed to improve intracellular delivery 
and increase the solubility of the peptide, and a linker between the two domains 
(SQP) [54]. The peptide has a cysteamine at its C-terminus, which improves the 
PEP-1 interaction with the lipid membrane [58]. PEP-1 forms a complex with the 
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cargo through non-covalent interactions. This complex is efficiently translocated 
in a large number of cell lines [54]. The mechanism of PEP-1 translocation with 
its cargo into higher eukaryotic cells is not well understood [59, 60]. Morris et al. 
proved, using scanning electron microscopy and dynamic light scattering, that 
PEP-1 forms nanoparticles with the cargo [61]. The particle’s size and 
morphology is unaffected by the size of cargo, but the molar ratio of PEP-1 to 
cargo has an important role in defining these parameters. After translocation, the 
PEP-1/cargo complex rapidly dissociates in the cytoplasm, the peptide localizing 
mostly in the nucleus while the cargo’s intracellular localization remains 
unaffected (if the cargo’s function is in the cytosol than it remains there) [54]. 
PEP-1/cargo nanoparticles enter cells independently of the endosomal pathway 
and deliver the cargo efficiently in a fully biological active form to a wide range of 
cell lines [53, 54]. An important criterion for designing a delivery system is the 
toxicity of the carrier. PEP-1 was tested on different cell lines, and no toxicity was 
observed for concentrations of peptide of 100 µM [54].  
Another common method of protein translocation involves making genes 
that fuse the peptide to the cargo protein and expressing the construct in 
Escherichia coli. One popular peptide is the trans-acting activator of transcription 
(TAT) from the human immunodeficiency virus (HIV-1). This peptide has been 
used to deliver proteins [62], oligonucleotides [63, 64], liposomes [65], and 
nanoparticles [66]. TAT targets the cargo to the nucleus [67]. A more efficient 
peptide developed by Kim et al. [68], is designed to translocate important 
amounts of cargo into the cytosol. A series of sequences were designed and 
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tested on live cells. The sequence YGR2AR6 proved to be the most efficient in 
translocating β-galactosidase into several cell lines. After transduction, the 
peptide is cleaved in the cells by cytoplasmic enzymes and the cargo is released 
[68]. PEP-1 and the YGR2AR6 peptide were selected to translocate α-synuclein 
into higher eukaryotic cells. These peptides were chosen because of their ability 
to translocate large amounts of cargo into the cells and because of their 
capability to release the cargo into the cytosol.   
1.4 In-cell NMR  
1.4.1 In-cell NMR in E. coli 
1.4.1.1 Protein-Protein Interactions and Signal Transduction 
In-cell NMR spectroscopy characterizes one protein at a time while a more 
interesting and valuable aspect would be to characterize the whole complex by 
enriching all the proteins in the complex with one of the NMR active nuclei. 
Unfortunately, the resulted spectra would be too complicated to analyze.  
Shekhtman et al. [69] developed a method to study a protein in a complex by 
NMR. STINT-NMR (structural interactions using NMR) works by enriching only 
one protein in a complex and expressing it using the orthogonal induction 
system. Shekhtman et al. [69] overexpressed ubiquitin in 15N-enriched media by 
using the pBAD promoter. Next, the cells were collected by centrifugation and 
resuspended in unenriched media. The PT7/lac system was used to express the 
other protein in the complex. The interactions between the two proteins were 
noted by changes in the width or chemical shift of the resonances of the enriched 
protein.  
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Protein phosphorylation can be studied using NMR. Shekhtman‘s 
laboratory used STINT-NMR to understand signal transduction by simultaneously 
expressing three proteins: the target protein (ubiquitin), a large (>100 kDa) 
heterodimeric affector complex, and a specific kinase [70]. The ubiquitin was 
expressed under three conditions: alone, with coexpression of the affector 
complex, and with coexpression of the complex and kinase. They determined the 
interactions between ubiquitin and the complex and phosphorylation of ubiquitin 
induced by expression of the kinase. Changes induced by phosphorylation can 
be sensed by ubiquitin even though the complex is large. 
1.4.1.2 Intrinsically Disordered Proteins  
Intrinsically disordered proteins lack stable tertiary structure in dilute 
solution. Many members of this recently defined class play important roles in cell 
signaling, regulation, and control. Disordered proteins are associated with 
disease states, including amyloidoses and neurodegenerative disorders [71]. 
Although the properties of globular proteins do not change significantly over a 
wide range of solution conditions, the properties of intrinsically disordered 
proteins can vary [72]. This sensitivity to solution conditions should make them 
attractive targets for studies of physiologically relevant conditions. Despite this 
sensitivity, and the known relationships between protein disorder and disease, 
little is known about the intracellular structure of this protein class. Disordered 
proteins are easier to detect by in-cell NMR than are globular proteins of the 
same size. This increased sensitivity arises from differences in global and local 
motions for globular and disordered proteins [73]. Because of their rigidity, the 
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relaxation rates for globular proteins are most sensitive to global motion, which is 
described by a single rotational correlation time. Disordered proteins, on the 
other hand, are flexible. Their motions involve an ensemble of interconverting 
conformers where different residues have different effective correlation times. 
That is, the flexible nature of disordered proteins mitigates the deleterious effect 
of viscosity on their spectra. 
The first in-cell NMR study of an intrinsically disordered protein was 
reported by Dedmon et al. [74]. The protein, FlgM, regulates flagellar synthesis 
upon binding a transcription factor. The intracellular environment in E. coli 
causes the C-terminal half of FlgM to gain structure while the N-terminal half 
remains unstructured. Similar characteristics were noted in vitro in solutions 
containing high levels of glucose, bovine serum albumin (BSA), and ovalbumin. 
These data show that it is important to study disordered proteins under 
physiologically relevant conditions. α-Synuclein, a 140-residue cytosolic 
eukaryotic protein, is the primary component of the intracellular protein 
aggregates called Lewy bodies [73]. These aggregates are present in substantia 
nigra neurons of patients with Parkinson’s disease. Studying α-synuclein under 
crowded conditions may provide information related to its role in the disease. 
McNulty et al. [75] used in-cell NMR to investigate the structure of α-synuclein in 
E. coli. These authors first noticed a difference between 1H-15N HSQC spectra in 
dilute solution acquired at 10 and 35 °C [76]. Spectra collected at the higher 
temperature presented fewer cross-peaks (~35) compared to spectra collected at 
10 °C (~70). Experiments using an α-synuclein comprising only the first 100 
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residues showed that cross-peaks in the spectrum acquired at 35 °C are from the 
C-terminal third of the protein. This temperature dependent behavior was 
associated with an increase in hydrodynamic radius and a gain in the level of 
secondary structure at 35 °C. These changes were reversible when the 
temperature was decreased to 10 °C. The authors concluded that the N-terminal 
two-thirds of the protein exchanges between a more structured extended state 
and more disordered but more compact state. Heating the protein increases the 
rate of exchange between these states, causing the crosspeaks to disappear. 
The in-cell spectrum of α-synuclein at 35 °C looks like the spectrum 
recorded at 10 °C in dilute solution. In vitro experiments in 300 g/L BSA yield 
spectra similar to those acquired from E. coli at 35 °C. These observations give 
rise to the idea that crowding in these cells or in vitro keeps α-synuclein in a 
disordered but more compact state. These conclusions, however, have been 
questioned. Croke et al. [77] suggest the difference between the in-cell and dilute 
solution results reflects a mismatch in pH between the samples, which results in 
higher amide proton exchange rates and a concomitant loss of resonances at 35 
°C. 
1.4.1.3 The effect of intracellular crowding on proteins 
Li et al. [78] studied globular and disordered proteins in E. coli. Globular 
15N-enriched proteins cannot be detected in bacteria by using NMR. While 1H-15N 
HSQC spectra are not resolved in intact cells, the 19F spectra can provide good 
information about intracellular dynamics of globular and disordered proteins. 
Small globular proteins (~10 kDa) labeled with 3-fluoro-L-tyrosine give resolved 
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spectra while larger size proteins (up to ~100 kDa) provide good spectra only 
when labeled with trifluoromethyl-L-phenylalanine.   
Schlesinger et al. [79] studied the effect of E. coli cytosol on a variant of 
Protein L. The globular protein, Protein L (~7 kDa), is folded in cells and in dilute 
solution but the variant having seven lysine residues replaced by glutamic acids 
is mostly unfolded in dilute solution at room temperature. The Protein L variant is 
unfolded in cells suggesting that nonspecific interactions between cytoplasmic 
components are more important than the excluded-volume effect. 
1.4.1.4 Determination of protein structure in E. coli 
The structure of the heavy-metal binding protein TTHA1718 from Thermus 
thermophilus HB8 was determined de novo in E. coli [80]. This study represents 
one of the most important breakthroughs of the in-cell NMR in prokaryotic cells. 
The 3D NMR spectra were collected and the calculated structure reveals that the 
protein structure in E. coli is similar with the structure of the protein in vitro. 
1.4.2 In-cell NMR in Higher Eukaryotic Cells  
In-cell studies in E. coli will continue to provide fundamental information 
about crowding effects, but the medical relevance of higher eukaryotic cells 
makes them attractive targets for in-cell NMR. In addition, in-cell NMR in higher 
eukaryotic cells may be easier because the cytosol of eukaryotic cells seems to 
have a lower apparent viscosity [81]. 
The first in-cell NMR study of isotopically enriched proteins in nucleated 
higher eukaryotic cells was conducted in Xenopus laevis oocytes [82]. Their large 
size (~1 mm diameter) allows microinjection of isotopically enriched protein into 
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the cytosol. The B1 domain of streptococcal protein G (GB1) was expressed and 
15N-enriched in E. coli, purified, and injected into 200 oocytes. The authors 
studied a range of intracellular GB1 concentrations between 50 and 500 µM. The 
positions of the GB1 resonances in the HSQC spectra remained the same in 
dilute solution, in oocytes, and in solutions containing 250-300 mg/mL BSA, 
showing that neither crowding nor the environment in the cell changes the 
structure of GB1. Different behavior was observed, however, in terms of cross-
peak intensity. Resonances of amides involved in intramolecular hydrogen bonds 
showed diminished intensity in cells and in BSA compared to dilute solution. This 
observation is consistent with the idea that more dynamic parts of the protein are 
less affected by the increased viscosity in cells [73]. Sakai et al. [83] studied 
protein behavior after microinjection of 15N-enriched ubiquitin and calmodulin into 
Xenopus oocytes. The in-cell spectrum of wild-type ubiquitin presented fewer 
resonances compared to its in vitro spectrum. Mutations in the hydrophobic patch 
on the β-sheet of ubiquitin confirmed that the loss of the resonances is 
associated with interactions between ubiquitin and other proteins. Calmodulin 
spectra in oocytes presented two patterns correlated with the presence or 
absence of extracellular calcium ions. When calcium ions were coinjected with 
the calcium-free protein, the in-cell spectrum was characteristic of calcium-bound 
calmodulin, while the spectrum was characteristic of the calcium-free form if 
calcium was not coinjected. These observations show that the physiological 
intracellular calcium concentration (~0.1 µM) does not affect calcium-free 
calmodulin. We end this section with a note of caution. Oocytes are fragile, so 
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conditions that preserve them will facilitate longer acquisition times, thereby 
decreasing the amount of protein required for detection by NMR. Bodart et al. 
[84] showed that oocytes can be preserved by embedding them in a 20% Ficoll 
solution. The embedded cells remained intact for 20 h, allowing the detection of 5 
µM intracellular protein. Nevertheless, care must be taken to monitor protein 
leakage. Sakai et al. [85], working with enriched calmodulin and ubiquitin, have 
developed an oocyte coinjection method involving GFP that is useful for 
detecting leaks. 
1.4.2.1 Phosphorylation in Higher Eukaryotic Cells  
Selenko et al. [86] used NMR to detect phosphorylation of the viral SV40 T 
antigen in intact X. laevis oocytes by endogenous casein kinase 2 (CK2). CK2 
phosphorylates two serine residues in the regulatory region of the T antigen, 
altering the nuclear-import properties of the full-length protein. These 
investigators provide the first NMR observation of an in vivo protein substrate 
phosphorylation event inside living cells by an endogenous protein kinase. Time-
resolved NMR spectra in oocytes show sequential phosphorylation of the 
substrate. The investigators conclude that CK2 phosphorylation occurs in a two-
step reaction with intermediate release of the substrate and preference of the 
kinase for the unphosphorylated substrate. The results obtained in oocytes agree 
with NMR spectra acquired in dilute solution and in egg extracts, implying that 
the kinetics of phosphorylation are not affected by macromolecular crowding. 
Phosphorylation of the intrinsically disordered protein tau in X. laevis oocytes has 
also been studied with NMR [84]. 
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Bodart et al. [84] detected novel signals in the in vivo spectrum that they 
assigned to phosphorylated residues of tau. Comparison of the in-cell spectrum 
to the in vitro spectrum containing two known oocyte kinases revealed shifts in 
resonance positions. These shifts suggest that unidentified kinases in oocytes 
may alter the positions of resonances observed in vitro. This study provides the 
first analysis of an intrinsically disordered protein in live eukaryotic cells by in-cell 
NMR. 
1.4.2.2 In-cell NMR in human cells 
In-cell NMR spectra of 15N-enriched ubiquitin and the B1 domain of 
streptococcal protein G (GB1) were conducted in HeLa cells [87]. The proteins 
were either fussed to the cell-penetrating peptides or bound trough disulphide 
links. Upon translocation, the proteins are released in the cytosol by specific 
intracellular enzymes that cleave the covalent bond or by the reduced 
intracellular pH for the disulphide links. The intracellular structure of all the 
proteins tested is similar with their in vitro NMR structure indicating that 
intracellular crowding does not have an effect on these proteins. However, 
important information for drug screening was obtained for FKBP12 when the cells 
were treated with extracellular immunosuppressants. 
1.4.3 Caveats of in-cell NMR 
A series of caveats are associated with NMR spectroscopy in live cells 
and Ito and Selenko reviewed them recently [88]. These include: the insensitivity 
of NMR spectroscopy [89] which requires large amounts of 15N-enriched or 19F-
labeled protein in the cells, the cells viability during spectra acquisition, binding of 
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the protein to other macromolecules or membranes in cells, protein leakage from 
the cells, degradation and instability of translocated proteins in cells, and sample 
inhomogeneity.  
Studying α-synuclein in live cells and its interaction with the membranes 
using NMR provides atomic level information about this protein inside the cells 
and helps elucidate the function of α-synuclein in Lewy bodies formation in 
Parkinson’s disease. This information may be relevant for prevention and 
treatment of this debilitating disease.       
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CHAPTER 2 
 
Interaction of α-Synuclein and its A30P Variant with Vesicles of 
Composition Similar to Mitochondrial Membranes 
 
Summary 
 
α-Synuclein, an intrinsically-disordered protein associated with 
Parkinson’s disease, interacts with mitochondria but the details of this interaction 
are unknown. Cardiolipin is the main anionic lipid in mitochondria where almost 
all of its acyl chains possess two double bonds. We probed the interaction of α-
synuclein and its A30P variant with lipid vesicles by using fluorescence 
anisotropy and 19F nuclear magnetic resonance. Both proteins interact strongly 
with large unilamellar vesicles of composition similar to that of the inner 
mitochondrial membrane, which contains cardiolipin, but have no affinity for 
vesicles mimicking the outer mitochondrial membrane, which lacks cardiolipin. 
The 19F data show that the interaction involves α-synuclein’s N-terminal region. 
These data indicate that the middle portion of the protein, which contains the 
KAKEGVVAAAE repeats, is involved in binding, probably via electrostatic 
interactions between the lysines and cardiolipin. However, the saturation of the 
cardiolipin acyl side chains also determines the strength of α-synuclein binding. 
Eliminating one double bond increases affinity, while complete saturation 
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dramatically decreases affinity. Increasing the temperature increases the binding 
of wild-type, but not the A30P variant. These data suggest that membrane 
packing density is important in determining α-synuclein affinity. This idea was 
confirmed by examining the anisotropy of 1,6-diphenyl-1,3,5-hexatriene in the 
presence of vesicles with or without the proteins. The results advance our 
understanding of α-synuclein’s interaction with mitochondrial membranes.  
2.1 Introduction 
Parkinson’s disease and other neurodegenerative disorders are 
characterized by cytoplasmic neuronal inclusions known as Lewy bodies [1-4]. α-
Synuclein, a 140-amino acid intrinsically disordered protein, is the main 
component of Lewy bodies [5-8]. The protein (Figure 2.1 A) comprises a 
positively-charged N-terminal region (residues 1-60) with an imperfect consensus 
repeat KTKEGV involved in lipid binding, a hydrophobic middle segment known 
as the NAC region (Non Amyloid Component, residues 61-95), and a negatively-
charged C-terminal region (residues 96-140) [9, 10].  
The protein helps maintain SNARE-complex assembly at presynaptic 
vesicles through its C-terminus, while the N-terminus is anchored to the vesicle 
[11]. Its function is important during increased synaptic activity when the nerve 
terminals repeatedly release neurotransmitters, which requires the assembly and 
disassembly of the SNARE complex. The protein is also involved in aging, but 
the reason for its age-related loss of function is unknown [11].  
α-Synuclein localizes not only to the presynaptic neural terminals but also 
to other subcellular compartments such as mitochondria [12, 13]. This 
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localization is associated with mitochondrial dysfunction [13-15] including 
impaired complex I function [12, 16], oxidative stress [17], and mitochondrial lipid 
abnormalities [16]. More specifically, a decrease in cardiolipin (CL) and  a 
change in its acyl side chains were noted in mitochondria from the brains of mice 
lacking α-synuclein [16]. The side chain changes involve a reduction in 
polyunsaturated fatty acids [16, 18] and an increase in saturated fatty acids [16]. 
Since CL is a mitochondria-specific phospholipid, the implied importance of α-
synuclein at the mitochondrial level is evident. Although the exact link between 
the loss of α-synuclein and the decrease in CL is unclear, the findings suggest 
that α-synuclein helps control intracellular transport of lipids [16].  
The interaction of α-synuclein with vesicles of different lipid composition 
[19], phospholipid headgroups [20], sizes [21], and surfaces [22, 23] has been 
studied. Despite these efforts little is known about the interaction of α-synuclein 
with the mitochondrial membrane, the mechanism of α-synuclein transport 
through the outer mitochondrial membrane, and the localization of the protein in 
the inner mitochondrial membrane [17].  
We used fluorescence anisotropy and high resolution nuclear magnetic 
resonance spectroscopy (NMR) to investigate the interaction of wild-type α-
synuclein and one of its familial Parkinson’s disease variants [24], A30P, with 
large unillamelar vesicles (LUVs) having lipid compositions similar to the inner 
and outer mitochondrial membranes. We evaluated the importance of CL as well 
as the effect of saturated and unsaturated CL acyl side chains on α-synuclein’s 
interaction with LUVs that mimic the inner mitochondrial membrane. We also 
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investigated the effect of temperature on affinity, and using 19F-labeled α-
synuclein, we determined which region of the protein interacts with LUVs 
containing CL. The results advance our understanding of α-synuclein’s 
interaction with mitochondrial membranes.    
2.2 Materials and Methods 
2.2.1 Expression, Purification, and Labeling of Human α-Synuclein 
and its A30P Variant  
Wild-type α-synuclein, A30P α-synuclein, V3C α-synuclein and V3C;A30P 
α-synuclein were expressed from a T7-7 plasmid in Escherichia coli BL21-
Gold(DE3) competent cells (Stratagene Cloning Systems, La Jolla, CA). The 
proteins were purified as described [25, 26].  
The V3C mutation at position 3 was made by using a Stratagene site-
directed mutagenesis kit. The cysteine was used to attach Alexa Fluor 488 
(Invitrogen, Carlsbad, CA). For labeling, 12 mg of V3C α-synuclein were 
dissolved in sterile, degassed water to a final concentration of 2 mg/mL. Tris(2-
carboxyethyl)phosphine and NaHCO3 were added in a 10-fold molar excess over 
the protein. The mixture was incubated at room temperature with shaking for 30 
min. Next, Alexa Fluor 488 C5-maleimide was added in a 10-fold molar excess 
over protein and the mixture incubated at room temperature with shaking for 2 h. 
The labeled protein was purified with gel filtration chromatography by using a 
Superdex 75 column eluted with 20% acetonitrile in phosphate buffered saline 
(NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM, KH2PO4 1.8 mM). The labeled 
protein was dialyzed against water.  
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The extinction coefficient of the dye at 494 nm (71,000 M-1cm-1) was used 
to quantify the labeled protein. The Lowry method (Pierce, Rockford, IL) was 
used to quantify the total protein. The degree of labeling was 84% for V3C α-
synuclein and 99% for V3C;A30P α-synuclein.  Aliquots containing 1 mg of 
labeled protein were lyophilized and stored at –80 °C.  
For NMR experiments, wild-type and Y125F α-synuclein labeled with 3-
fluoro-L-tyrosine were prepared as described [27].  
2.2.2 Cell Culture and Mitochondria Isolation  
Human epithelial carcinoma cells (HeLa) from ATCC were cultured in 
Dulbelcco’s modified Eagle’s medium (Invitrogen) supplemented with 10% fetal 
bovine serum, penicillin and streptomycin (100 µg/mL). The cultures were 
incubated at 37 °C in 5% CO2. Mitochondria were isolated from HeLa cells (2 x 
107 cells) by using a Mitochondria Isolation Kit for Cultured Cells (Pierce, 
Rockford, IL). Their activity was tested by assessing the cytochrome c oxidase 
activity with the Mitochondria Activity Assay Kit (BioChain Institute, Inc., 
Haywatd, CA). 
2.2.3 Mitochondrial Import of α-Synuclein  
Freshly isolated mitochondria were incubated with fluorescently-labeled α-
synuclein in the presence of an energy mixture and transport buffer as described 
[28]. Trypsin was used to remove α-synuclein attached to the surface of 
mitochondria. Mito Tracker Red CMXRos (Invitrogen) was used to stain the 
active mitochondria after protein import and trypsinization. Fused silica and glass 
microscope slides were prepared as described [29]. Mitochondria containing α-
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synuclein were allowed to attach to the poly-L-lysine coated slide for 30 min and 
then rinsed with minimal media. α-Synuclein import was tested using confocal 
microscopy on an inverted laser scanning microscope (Zeiss 510 Meta, 
Thornwood, NY) equipped with a 63 x, 1.4 NA, Plan-Apochromat, oil immersion 
objective. 
2.2.4 Vesicle Preparation  
Components were purchased from Avanti Polar Lipids, Inc. (Birmingham, 
AL) in chloroform, except cholesterol (CH, from ovine wool), which was dissolved 
in chloroform to a concentration of 1 mg/mL and stored at –20 °C. The 
components were used without further purification.  
Aliquots of the components, in chloroform, were mixed in glass vials and 
the solvent removed overnight in a vacuum concentrator. The dried mixtures 
were suspended in 1 mL of 50 mM sodium phosphate buffer, pH 7.4, to a final 
lipid concentration of 2 mM. The following phospholipids were used for preparing 
LUVs:  CL (bovine heart), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1',3'-bis[1,2-dimyristoyl-sn-
glycero-3-phospho]-sn-glycerol (TM CL), and 1',3'-bis[1,2-dioleoyl-sn-glycero-3-
phospho]-sn-glycerol (TO CL). Figure 2.1 B shows the structures of CLs.  
Vesicles of composition DOPC:DOPE:CL:CH 2.0:1.3:1.0:0.6 molar ratio 
and DOPC:DOPE:CH 4.0:2.0:0.9, corresponding to inner and outer membrane of 
mitochondria [30], respectively, were prepared. LUVs with different ratios of CL 
(1.0, 0.8, 0.5, and 0) or different CL acid side chains (TM and TO) were also 
prepared.  
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LUVs were prepared by multiple extrusion [20, 31, 32] through a 0.1 µm 
polycarbonate membrane (Whatman Inc., Sanford, ME). For NMR experiments, 
the vesicles were prepared with the same protocol, but at a concentration of 4 
mM. The dried mixture corresponding to the inner mitochondrial membrane was 
resuspended in 50 mM sodium phosphate buffer, pH 7.4, containing 10% D2O. 
The final concentration of 19F labeled protein in the NMR tube was 100 µM and 
the protein:lipid molar ratio was ~1:100.  Protein in buffer alone was used as a 
reference. 
2.2.5 Fluorescence Anisotropy of Labeled Proteins  
The experiments were conducted on a FluoroLog®-322 spectrofluorometer 
(HORIBA Jobin Yvon Inc., Edison, NJ) with an excitation wavelength of 495 nm 
and an emission wavelength of 519 nm. Four hundred µL of protein (100 nM) in 
50 mM sodium phosphate buffer, pH 7.4, were titrated with LUVs at 25 or 37 °C. 
Each point is the average of five measurements, and each condition was tested 
in triplicate. Control measurements using only LUVs or unlabeled wild-type α-
synuclein in the same buffer were performed to assess background fluorescence, 
which was negligible. The anisotropy was calculated as described [33]. The 
dissociation constants (Kd) were calculated by fitting the data to a one site 
binding model (SigmaPlot 11.0). 
2.2.6 DPH Fluorescence Anisotropy 
1,6-Diphenyl-1,3,5-hexatriene (DPH) was incubated with LUVs containing 
TO, TM, or CL IM for one h at room temperature either in the presence or 
absence of proteins.  The final molar lipid to DPH ratio was 300:1. Fluorescence 
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anisotropy was recorded at 25 °C by using an excitation wavelength of 360 nm 
and an emission wavelength of 440 nm. Fluorescence anisotropy was also 
measured at 37 °C for CL IM LUVs in the presence or absence of wild-type or 
A30P α-synuclein. The result for each condition represents the average of five 
measurements. 
2.2.7 NMR   
19F spectra were acquired at 25 °C on a Varian Inova 600 MHz 
spectrometer equipped with a 5 mm triple resonance probe. The spectra 
comprised 2048 transients with a 30 kHz sweep width. The 19F chemical shifts 
were referenced to trifluoroethanol at 0 ppm. The experiments were conducted in 
triplicate.  
 
2.3 Results 
2.3.1 In vitro Mitochondrial Import of α-Synuclein 
 
Fluorescently-labeled α-synuclein localized in isolated mitochondria 
(Figure 2.2A). Mito Tracker Red CMXRos is an indicator of active mitochondria 
because its accumulation is related to membrane potential. The red fluorescence 
shows that mitochondria are active after protein import and trypsinization (Figure 
2.2B). Co-localization of fluorescently-labeled protein and Mito Tracker Red 
indicates that the protein is localized in close proximity of the membranes, not in 
the matrix (Figure 2.2D). These findings agree with those of Devi et al. [15]. To 
better understand the distribution of α-synuclein in the inner and outer 
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membrane, we used lipid vesicles with a composition similar to these 
membranes. 
 
2.3.2 Interaction with LUVs Having Lipid Compositions Similar to the 
Inner and Outer Mitochondrial Membrane 
Mitochondria contain 25.3% phospholipid by mass [30]. In terms of 
phospholipid composition, the mitochondria comprise 40.8% phosphatidyl 
choline, 37.4% phosphatidyl ethanolamine, 19.1% CL, and ~3% phosphatidyl 
inositol. The major phospholipids of the outer membrane are phosphatidyl 
choline (55.2%), and phosphatidyl ethanolamine (25.3%). The major 
phospholipids of the inner membrane are phosphatidyl choline (44.5%), 
phosphatidyl ethanolamine (27.7%), and CL (21.5%). CL is essentially absent 
from the outer membrane [30].  
Fluorescence anisotropy was used to quantify the interaction of 
fluorescently-labeled V3C α-synuclein and V3C;A30P α-synuclein with LUVs. 
Alexa Fluor 488 dye was chosen because of its high photostability [34]. Labeling 
at position 3 was selected because this region of the protein is highly dynamic, 
decreasing the possibility that the modification will disrupt the native 
conformation [35]. The average diameter of the LUVs, as determined by dynamic 
light scattering, is ~140 nm (Figure 2.3A-D), consistent with values for vesicles 
extruded through membranes with 100 nm pores [20, 31]. The vesicles were 
stable for at least three days if kept at 4 °C in 50 mM sodium phosphate buffer, 
pH 7.4. Nevertheless, the vesicles were used within 48 h. The presence or 
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absence of CL (Figure 2.3A and B) or CH (Figure 2.3C and D) does not affect the 
size of the vesicles.     
First, we studied the interaction of fluorescently-labeled proteins with 
LUVs having a molar DOPC:DOPE:CH ratio of 4.0:2.0:0.90, which corresponds 
to the composition of the outer membrane. No change in the anisotropy was 
noted when titrating 100 nM protein with LUVs, suggesting no affinity of 
fluorescently labeled V3C or V3C;A30P α-synuclein for this type of vesicle 
(Figure 2.4 A and B).  
LUVs with a molar ratio corresponding to the inner membrane 
(DOPC:DOPE:CL:CH of 2.0:1.3:1.0:0.60) gave strikingly different results; both 
the wild-type protein and the A30P variant bind with sub mM dissociation 
constants. As shown in Table 1, V3C α-synuclein binds slightly more strongly (Kd 
130 µM) than the V3C;A30P variant (Kd 210 µM). Since only the inner membrane 
contains CL, these observations implicate CL in the binding of α-synuclein and 
are consistent with studies showing that α-synuclein interacts with vesicles 
containing anionic phospholipids [10, 20, 36, 37].     
2.3.3 Importance of CL 
α-Synuclein is mostly associated with the inner membrane of  
mitochondria in brains from patients with Parkinson’s disease [12, 15]. Brains of 
mice lacking α-synuclein have reduced levels of only CL and 
phosphatidylglycerol (a CL precursor) [16]. Since CL is mitochondria-specific, we 
decided to investigate α-synuclein binding to LUVs containing different amounts 
of this phospholipid.  
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The data are shown in Figures 2.3, and the Kd values are compiled in 
Table 1. LUVs containing DOPC, DOPE, and CH in molar ratios corresponding to 
the inner mitochondrial membrane were prepared with 100%, 80%, 50%, and 0% 
CL, where 100% represents the normal amount in the inner membrane. For V3C 
α-synuclein, decreasing the CL by 20% causes less than a two-fold increase in 
Kd but halving the CL increases Kd by a factor of 6 (Table 1). No binding was 
noted when CL was absent (Figure 2.5 A). These findings show that CL is 
essential for the interaction between α-synuclein and the inner mitochondrial 
membrane.  
We also studied the interaction of the A30P variant with these LUVs. The 
decrease in affinity is even stronger for the variant than it is for the wild-type 
protein (Figure 2.5 B).     
2.3.4 Effect of the CL Acyl Group on Binding  
Mitochondria from mice lacking α-synuclein have 51% more saturated 
fatty acids and 25% less n-6 polyunsaturated fatty acids, but the content of 
monounsaturated fatty acids is unchanged [16]. To investigate the effect of such 
changes on α-synuclein binding, LUVs with a molar ratio corresponding to the 
lipid composition of the inner membrane were prepared by using CL with a 
saturated acyl side chain (TM CL) and CL with one single double bond in the acyl 
chain (TO CL) (Figure 2.1 B).  
The results are shown in Figure 2.6, and the Kd values are compiled in 
Table 1. The V3C variant binds LUVs with one double bond per side chain more 
strongly (Kd  67 µM) than those LUVs containing two double bonds(Kd 130 µM). 
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Complete saturation, however, abrogates binding. The affinity of A30P α-
synuclein for LUVs containing one double bond per side chain (Kd 153 µM) is 
nearly the same as its affinity for LUVs with two (Kd 210 µM), but no binding was 
noted with only saturated side chains. We conclude that α-synuclein prefers the 
LUVs with unsaturated side chains, and that the affinity for LUVs with saturated 
acyl side chains is negligible.  
2.3.5 Positional Information 
Since V3C α-synuclein and V3C;A30P α-synuclein are both labeled with 
the dye at a single position (Figure 2.1 A), the fluorescence anisotropy studies 
provide information about overall protein binding but not positional information. 
19F NMR was used to test the effect of chain saturation and to determine if the 
specific regions of α-synuclein bind differently. 19F is sensitive to its environment, 
such that small changes in the structure of a labeled region are easily detected.  
α-Synuclein has four tyrosines, one at position 39 in the N-terminal region 
and the others near the C-terminus at the positions 125, 133, and 136 (Figure 2.1 
A). The 19F NMR spectrum of 3-fluoro-tyrosine-labeled wild-type α-synuclein in 
buffer alone exhibits only three resonances (Figure 2.7 A). As shown by Li et al. 
[27], who assigned all the resonances, the middle resonance is a composite from 
tyrosines 39 and 125. To avoid this problem, we used the Y125F variant to 
eliminate the overlap (Figure 2.7 B).  
Spectra acquired in the presence of vesicles containing CL with two (CL), 
one (TO), and no (TM) double bonds are shown in Figure 2.7 C, D, and E, 
respectively. The resonances from positions 133 and 136 are unchanged by the 
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LUVs, but the resonance from position 39 decreases (Figure 2.7 C-E), indicating 
the interaction of the N-terminal region of the protein with the vesicles.  The 
relative decrease of the position 39 resonance depends on the acyl side chain. 
The largest decrease occurs for the CL with two double bonds (TO CL) and the 
smallest for the completely saturated CL (TM CL), consistent with the order from 
the fluorescence anisotropy described above.  
2.3.6 Temperature and Binding 
Heat increases membrane fluidity. In Table 1 we compared the affinities at 
25 °C (Figure 2.4 A and B) and 37 °C (Figure 2.8) of fluorescently-labeled V3C α-
synuclein and V3C;A30P α-synuclein for LUVs with a composition corresponding 
to the inner membrane. The affinity of V3C α-synuclein is two fold greater (Kd 59 
µM) at 37 °C than it is at 25 °C (Kd 134 µM), but the affinity of the V3C;A30P 
protein is unaffected.   
2.3.7 DPH Fluorescence Anisotropy 
The fluorescence anisotropy of DPH was used to examine the packing 
density of LUVs with different CL acyl side chains. The anisotropy depends on 
the type of phospholipid and its degree of saturation [38].  
The data indicate that in buffer, at 25 °C, LUVs containing TO CL are as 
well packed as CL IM LUVs, but both are better packed than TM CL LUVs 
(Figure 2.9).α-Synuclein perturbs the membrane packing density. Wild-type and 
A30P α-synuclein reduce the anisotropy for all three types of LUVs. The 
decrease is comparable for wild-type and A30P α-synucleins. Studies conducted 
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at 37 °C also show a decrease in anisotropy for CL IM vesicles in the presence of 
both wild-type and A30P α-synuclein (Figure 2.9, inset). 
2.4 Discussion 
α-Synuclein interacts with isolated mitochondria from HeLa cells and is 
imported in the proximity of the inner membrane but it is not transported into the 
matrix. 
α-Synuclein has no affinity for LUVs with the lipid composition of the outer 
mitochondrial membrane, which lacks CL. This observation is consistent with 
studies showing that α-synuclein enters mitochondria via the protein import 
channel [12] rather than through lipid interactions.  
A significant affinity was noticed for both the wild-type protein and the 
A30P variant for LUVs with a composition similar to that of the inner 
mitochondrial membrane, with the V3C α-synuclein having slightly higher affinity 
(Figure 2.4). Vesicles with the composition of the inner mitochondrial membrane, 
but lacking CL, do not bind α-synuclein. Consistent with this conclusion, a 
decrease in CL reduces α-synuclein affinity (Figure 2.5 A and B), with the affinity 
of the A30P variant decreasing more than the affinity of the wild-type protein 
(Figure 2.5 B). These observations show the importance of CL in the inner 
mitochondrial membrane for α-synuclein localization. The increased affinity of α-
synuclein for LUVs made from phospholipids with unsaturated side chains was 
confirmed [16]. However, in our study α-synuclein binds more strongly to the TO 
CL, which contains one double bond per acyl side chain compared to the CL, 
which contains two. To better understand the affinity of α-synucleins for CL 
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vesicles containing different fatty acids we investigated the vesicle packing 
density by using DPH fluorescence anisotropy. 
 The fluorescence anisotropy of DPH embedded in a LUV provides 
information about membrane fluidity, and hence the packing density of its acyl 
side chains. High packing density results in lower fluidity, and increased DPH 
anisotropy [39]. The data at 25 °C indicate that TO CL and CL IM vesicles are 
better packed than TM CL LUVs. That is, more water penetrates TM CL LUVs 
and fewer DPH molecules are inside the vesicles or are strongly interacting with 
saturated acyl side chains compared to TO CL and CL IM vesicles, reducing the 
fluorescence anisotropy. DPH fluorescence anisotropy decreases drastically 
when wild-type or A30P α-synucleins were added to LUVs containing TO, TM, or 
IM CL (Figure 2.9). The DPH fluorescence anisotropy data (Figure 2.9) correlate 
with binding constants (Table 1); stronger protein binding leads to decreased in 
DPH anisotropy. These observations suggest that α-synuclein-vesicle 
interactions destabilize the membrane [37].  
Our 19F NMR data suggest that only the N-terminal region interacts with 
the vesicles. Others have shown that this region interacts with phospholipid head 
groups forming an α-helix, while the C-terminus remains unstructured [20, 21, 36, 
40]. The A30P variant has a lower affinity for anionic lipid vesicles compared to 
the wild-type protein [41-44]. We also observe a decrease in the affinity of A30P 
for all LUVs used compared to the wild-type protein (Table 1). These 
observations are consistent with the presence of proline at position 30, which 
interrupts the α-helix in the vesicle bound protein [37].  
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Increasing the temperature increases the fluidity of the vesicles, reducing 
their packing density. Binding of wild-type protein is stronger at 37 °C than it is at 
25 °C. The stronger binding at higher temperature suggests that the hydrophobic 
effect is important in α-synuclein membrane interaction. Taken together with the 
NMR and DPH data, it appears that the decrease in packing density at higher 
temperature exposes hydrophobic membrane surface, which interacts with 
hydrophobic residues on the α-helix formed. These findings are consistent with 
DPH data; wild-type α-synuclein induces a larger decrease in anisotropy 
compared to the A30P variant.  
To our knowledge, this is the first study where fluorescence anisotropy 
and NMR were combined to investigate the affinity of α-synuclein for lipid 
vesicles with a composition similar to mitochondrial membranes. The data 
explain why α-synuclein has a high affinity for the inner membrane (it contains 
CL), show that the hydrophobic effect plays a role in binding, and indicates that 
the interactions involve the N-terminal region of the protein. These two 
techniques can also be used to monitor binding affinity of α-synuclein to isolated 
mitochondria and mitoplasts. Investigation of interaction between mitochondria 
and α-synucleins and the localization of the proteins in different sub-
mitochondrial compartments should help elucidate the role of these proteins in 
the mitochondria dysfunction associated with neurodegenerative diseases.    
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2.5 Table and Figures 
 
 
 
 
Table 2.1 Dissociation constants (µM) for fluorescently-labeled α-synucleins with LUVs.* 
    OM CL 100% 
(IM) 
TO CL TM CL CL 80% CL 50% CL 0% IM 37 °C 
V3C 
 
- 130 ±20 67 ±3 3000 ±4000 210 ±20 850 ±120 - 59 ±3 
V3C;A30P 
 
- 210 ±20 153 ±7 - 680 ±150 1200 ±700 - 230 ±20 
*Data were acquired at 25 °C unless otherwise specified; OM, outer membrane; IM, inner membrane; - , Kd could not 
be estimated. 
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Figure 2.1 Schematic representation of α-synuclein and structural formulas 
of the CLs 
Schematic representation of α-synuclein (A) showing the four tyrosines (red), the 
position labeled with dye (green), and the A30P point mutation (blue). (B) 
Structural formulas of the CLs used to prepare LUVs. 
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Figure 2.2 Confocal images of mitochondria incubated with α-synuclein  
Isolated mitochondrion from HeLa cells incubated with fluorescently-labeled α-
synuclein (A), and Mito Tracker Red (B), differential interference contrast (C), 
and the merged images (D).  
A B 
C D 
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Figure 2.3 Size and polydispersity index of LUVs 
Size and polydispersity index (PDI) of vesicles having a composition similar with 
mitochondrial inner membrane with CL (A) and without CL (B). Size and 
distribution of vesicles having a composition similar with mitochondrial outer 
membrane with CH (C) and without CH (D).  
Radius (nm)             % Intensity           Width (nm) 
A B 
C D 
Radius (nm)             % Intensity           Width (nm) 
Radius (nm)             % Intensity           Width (nm) Radius (nm)             % Intensity           Width (nm) 
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Figure 2.4 Interaction of α-synucleins with OM and IM LUVs 
Interaction of fluorescently-labeled V3C α-synuclein (A) and V3C;A30P α-
synuclein (B) with LUVs having a composition similar to that of the inner ( ) and 
outer ( ) membranes. Error bars represent the standard deviations from triplicate 
experiments. 
 B 
 A 
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Figure 2.5 Interaction of α-synucleins with LUVs having different CL ratio 
Differential binding affinity of fluorescently labeled - V3C α-synuclein (A) and - 
V3C;A30P α-synuclein (B) to LUVs having a composition similar to the inner 
membrane but varying amounts of CL. Error bars represent the standard 
deviations from triplicate experiments. 
 A 
 B 
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Figure 2.6 Interaction of α-synucleins with LUVs containing CLs with 
different side chains 
Binding of fluorescently labeled - V3C α-synuclein (A) and - V3C;A30P α-
synuclein (B) to LUVs with a composition similar with inner membrane but 
different degrees of side chain saturation. Error bars represent the standard 
deviations from triplicate experiments. 
 B 
 A 
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Figure 2.7 19F NMR spectra of α-synuclein interaction with LUVs containing CLs with different side chains 
19F NMR spectra of tyrosine labeled wild-type (A) and Y125F (B) α-synuclein in buffer and the labeled Y125F variant in 
the presence of LUVs containing 100% CL (C), TO CL (D), and TM CL (E). Assignments are shown above the 
resonances (27). The molar ratio of protein to lipid is ~1:100. 
19F Chemical Shift (ppm) 
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39 
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133
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Figure 2.8 Interaction of α-synucleins with LUVs at 37 °C 
Interaction of fluorescently-labeled-V3C α-synuclein and -V3C;A30P α-synuclein 
with LUVs having a composition similar to the inner membrane at 37 °C. Error 
bars represent the standard deviations from triplicate experiments. 
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Figure 2.9 DPH anisotropy upon the interaction of α-synucleins with LUVs  
DPH anisotropy upon the interaction of α-synucleins with LUVs having different 
CL acyl side chains at 25 °C. The inset shows the anisotropy of CL IM in the 
presence and absence of α-synucleins at 37 °C. Error bars represent the 
standard deviations from 5 experiments. 
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CHAPTER 3 
 
Interaction of Proteins and Peptides with Plasma Membrane 
Studied by Fluorine NMR  
 
 
Summary 
 
 Fluorine NMR is a powerful tool for monitoring the insertion and 
conformation of cell-penetrating peptides upon interaction with cellular plasma 
membrane. To gain insight into the interaction of proteins and peptides with the 
membrane, α-synuclein and a modified α-synuclein with a cell-penetrating 
peptide covalently attached to its N-terminus were studied. By monitoring the 
decrease in the resonances of 3-fluoro-tyrosine labeled proteins, important 
information about the change in conformation of the protein in the presence of 
cells was noted. With α-synuclein, a decrease in the resonance from position 39 
was noted indicating that only the N-terminus interacts with the plasma 
membrane. However, when the fusion construct was incubated with cells, a 
decrease in the resonance from the peptide region was noted while no change 
was noted in the resonances from α-synuclein region.  Longer incubation, studied 
by using confocal fluorescence microscopy, reveals that the fusion construct 
translocates inside the cells but α-synuclein by itself did not cross the membrane 
in considerable amounts.   
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3.1 Introduction 
 
Biological components have to be delivered to intracellular compartments 
in significant amounts to observe effects in the cytosol, nucleus, or other 
organelles. The greatest barrier to delivery is the cellular plasma membrane. A 
series of delivery systems has been developed to overcome this problem.    
Cell-penetrating peptides cross the plasma membrane in an energy 
independent mode [1-3]. The peptide can be non-covalently attached to the 
cargo [4], overexpressed as fused biomolecule in bacteria (if the cargo is a 
protein) [5, 6], or bound through noncovalent (electrostatic and/or hydrophobic) 
interactions [7]. Several cell-penetrating peptides have been developed [5, 6]. 
One of the most popular peptide is the trans-acting activator of transcription 
(TAT) from the human immunodeficiency virus (HIV-1), which assures 
intracellular delivery of proteins [8], oligonucleotides [9, 10], liposomes [11], or 
nanoparticles [12]. TAT has a nuclear localization sequence that targets the 
fused proteins to the nucleus [13]. TAT fused to the N-terminus of α-synuclein 
was delivered to astrocytes [14] and PC12 [15] cells. Kim et al. [5] designed a 
cytoplasmic transduction peptide (CTP) derived from TAT, which delivers 
biomolecules to the cytoplasm rather than to the nucleus. Among the sequences 
tested, the eleven amino-acid sequence, YGR2AR6, proved most efficient in 
translocating β-galactosidase into several cell lines. After transduction, the 
peptide is cleaved by cytoplasmic enzymes, releasing its cargo. CTP has 
increased transduction potential compared with TAT [5].   
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Fluorine nuclear magnetic resonance spectroscopy (19F NMR) has a high 
sensitivity to the environment and allows the monitoring of interactions via the 
decrease in 19F signal intensity.  Also, it is a powerful probe for in-cell and in vivo 
studies because there is no background. Fluorine NMR is a suitable technique 
for studying protein-ligand interactions [16], fibril formation [17], and protein 
interaction with lipid vesicles [18], or sodium dodecyl sulfate micelles [19]. 19F 
NMR has also been used to study the interaction of peptides with small 
unilamellar vesicles, bicelles [20] and living cells [21]. 
Here, we used 19F NMR to study the interaction of wild-type α-synuclein 
and a CTP-α-synuclein construct with the plasma membrane of Chinese hamster 
ovary (CHO-K1) cells. We also investigated the effect of incubation time of the 
fused construct with the cells and the penetration of the peptide into the 
membrane. Longer incubation resulted in translocation of the protein across 
plasma membrane. Intracellular localization of the fluorescently-labeled construct 
was studied by confocal imaging in CHO-K1, human epithelial carcinoma (HeLa) 
cells, and cultured primary murine neurons. The results advance our 
understanding on the interaction of proteins and peptides with the plasma 
membrane and prove that 19F NMR is a valuable tool for probing these 
interactions.    
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3.2 Experimental Procedures 
3.2.1 Site-directed Mutagenesis  
The CTP-α-synuclein construct was created in two steps with a 
Stratagene site-directed mutagenesis kit. First, YGR2A was inserted at the N-
terminus of wild-type α-synuclein gene by using the following primers: 
Forward 5’-3’: 
GCAGGAGATATACATATGTATGGCCGTCGTGCGGATGTATTCATGAAAGG 
Reverse 5’-3’: 
CCTTTCATGAATACATCCGCACGACGGCCATACATATGTATATCTCCTGC 
Second, the R6 fragment was inserted using the following primers: 
Forward 5’-3’: 
GTATGGCCGTCGTGCGCGTCGTCGTCGTCGTCGTGATGTATTCATGAAAGG 
Reverse 5’-3’: 
CTTTCATGAATACATCACGACGACGACGACGACGCGCACGACGGCCATAC’ 
The insertions were confirmed with the sequencing primer:  
5’-GGGAGACCACAACGGTTTCCCTCTAG-3’.  
The V3C mutation was generated in the α-YGR2AR6 synuclein mutant by 
using the following primers: 
Forward 5’-3’:  
CGTCGTCGTCGTCGTCGTGATTGCTTCATGAAAGGACTTTCAAAG  
Reverse 5’-3’:  
CTTTGAAAGTCCTTTCATGAAGCAATCACGACGACGACGACGACG.  
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3.2.2 Expression and Purification of α-Synuclein Variants  
V3C α-synuclein and V3C CTP-α-synuclein were expressed in E. coli and 
purified as described by McNulty et al. [22] with modifications. Briefly, the pT7-7 
plasmids containing the wild-type, V3C, CTP or V3C CTP-α-synuclein genes 
were transformed into E. coli BL21-Gold(DE3) competent cells (Stratagene 
Cloning Systems, La Jolla, CA) and plated on Luria broth agar plates containing 
100 µg/mL ampicillin (LBAmp). A single colony was added to 50 mL of LBAmp and 
the culture was grown in a rotary shaker (225 rpm) for 16-18 h at 37 °C. The 
overnight culture was used to inoculate one liter of LBAmp, which was grown to an 
optical density at 600 nm of 0.6-0.8. The culture was induced with isopropyl-β-D-
thiogalactopyranoside to a final concentration of 1 mM, followed by protein 
expression for 4 h and then centrifugation (Sorvall RC-5B, SS-34 rotor) at 4000 
rpm for 30 min at 4 °C. The cell pellet was resuspended in 20 mL of lysis buffer 
(10 mM Tris, pH 8.0, 1 mM phenylmethanesulfonylfluoride, 1 mM 
ethylenediaminetetraacetic acid). Dithiothreitol (final concentration 1 mM) was 
added to the buffer for V3C wild-type and V3C CTP-α-synucleins. The cells were 
sonicated, the lysate was boiled and centrifuged. The supernatant was subjected 
to 10 mg/mL streptomycin sulfate precipitation and the supernatant subjected to 
(NH4)2SO4 precipitation (360 g/L). The pellet was resuspended in 20 mM Tris (pH 
7.7) and dialyzed (SnakeSkin, MWCO 3500, Pierce) against the same buffer, 
overnight at 4 °C. Next, the protein was purified by using anion exchange 
chromatography (AKTA FPLC UPC-900, Q-10 column, Amersham Pharmacia 
Biotech, Pittsburgh, PA) with a 1-M NaCl linear gradient at 4 °C followed by gel 
filtration chromatography (Superdex 75, Amersham Pharmacia Biotech). Protein 
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purity was assessed with sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE, BioRad, Hercules, CA) with Coomassie Brilliant 
blue staining. The insertion of YGR2AR6 was confirmed by using matrix-assisted 
laser desorption/ionization mass spectrometry (MALDI-MS) of Lys C digested 
samples. Purified α-synuclein was lyophilized and stored at –80 °C. α-Synucleins 
labeled with 3-fluoro-tyrosine (3FY) were expressed and purified as described by 
Li et al. [17]. 
3.2.3 Alexa Fluor Labeling  
Twelve mg of V3C α-synuclein or V3C CTP-α-synuclein were dissolved in 
sterile degassed water to a final concentration of 2 mg/mL. Tris(2-
carboxyethyl)phosphine and NaHCO3 were added to the mixture in a molar 
excess of 10:1 with respect to protein. The mixture was incubated at room 
temperature with shaking for 30 min. Next, Alexa Fluor 488 C5-maleimide 
(Invitrogen) was added in a ten-fold excess to α-synuclein. The mixture was 
incubated at room temperature with shaking for 2 h. The labeled α-synuclein was 
purified by gel filtration chromatography using Superdex 75 column and 20% 
acetonitrile with PBS as an eluent. The labeled protein was dialyzed against 
water, and the labeling efficiency was determined as described in the Alexa Fluor 
488 C5-maleimide labeling protocol (Invitrogen). The absorbance at 494 nm 
along with the extinction coefficient of 71,000 M-1cm-1 for Alexa Fluor 488 was 
used to quantify the labeled α-synuclein. The Lowry method was used to quantify 
the total amount of protein (Lowry protein assay kit, Pierce). Aliquots of 1 mg 
labeled protein were lyophilized and stored at –80 °C. 
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3.2.4 Cell Culture 
 Chinese hamster ovary cells (CHO-K1) and human epithelial carcinoma 
cells (HeLa) were obtained from the UNC Lineberger Cancer Center. Cells were 
seeded in 6-well glass plates (Corning Life Sciences, Lowell, MA) at a density of 
~2x105 cells/well with the cells in media (F-12 media for CHO-K1 cells and 
Dulbecco’s modified Eagle’s media for HeLa cells) supplemented with 10% fetal 
bovine serum (FBS), penicillin (100 units/mL), and streptomycin (100 µg/mL) at 
37 °C in 5% CO2. Primary murine sympathetic neurons dissected from the 
superior cervical ganglia were prepared as described by Deshmukh and Johnson 
[23] and then seeded at ~2x104 neurons/6-well collagen coated plate. The 
neurons were kept in AM50 media supplemented with 10% FBS, penicillin (100 
units/mL), streptomycin (100 µg/mL), and neuronal growth factor at 37 °C in 5% 
CO2. 
3.2.5 Fluorine NMR  
NMR spectra of 3FY-labeled α-synuclein were acquired at 37 °C on a 
Varian Inova 600 MHz NMR spectrometer at a frequency of 564.5 MHz using a 5 
mm triple resonance probe (Varian 600 H-F(C,X)). The CHO-K1 cells were 
incubated with 19F-labeled CTP-α-synuclein in F-12 media at 37 °C for different 
times. Aliquots from this mixture were mixed with equal volumes of 20% (w/v) 
Ficoll solution in F-12 media. The final sample contained 100 µM 19F CTP-α-
synuclein in F-12 media with ~1.5x107 cells/mL in 20% (w/v) Ficoll and 10% D2O. 
The interaction of the CHO-K1 cells with 19F-labeled wild-type α-synuclein and 
Y125F α-synuclein were studied in the same way. Cell viability was tested after 
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each NMR experiment by using the trypan blue exclusion assay. The viability 
was always greater than 90%.  
3.2.6 Fluorescence Image Acquisition and Quantification  
The cells were treated with fluorescently-labeled CTP-α-synuclein for 20 h. 
For imaging, four washing steps with PBS were performed after protein 
translocation. The cells were imaged in their complete media with a Zeiss 
confocal microscope equipped with LSM 5 software and a 40x oil objective. In 
addition, mitochondria were stained with Mito Tracker Red CMX Ros (Invitrogen) 
immediately prior to imaging. Fluorescence measurements were acquired with 
multichannel detection using 488 nm excitation (argon laser) for Alexa Fluor 488 
labeled protein and 543 nm excitation (HeNe1 laser) for Mito Tracker Red. 
Untreated cells were tested under the same conditions to assess 
autofluorescence.  
3.3 Results and Discussion 
3.3.1 CTP-α-Synuclein Expression, Purification and Labeling 
The fused construct (Figure 3.1) was expressed in E. coli. The CTP-α-
synuclein expression level is ~2/3 that of the wild-type protein under the same 
conditions as assessed by comparing the chromatograms of the two proteins at 
280 nm (Figure 3.2 A). The construct was pure as tested on SDS-PAGE (Figure 
3.2 B). The CTP insertion was confirmed by matrix-assisted laser 
desorption/ionization mass spectroscopy analysis (Figure 3.3). V3C α-synuclein 
and V3C CTP-α-synuclein were labeled with Alexa Fluor 488 maleimide dye at 
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efficiencies of ~90% and ~80%, respectively. The single band on the SDS PAGE 
indicates that the labeled sample is pure (Figure 3.4).  
3.3.2 Cell Suspensions for NMR Experiments 
 Studying the interaction of wild-type and CTP-α-synuclein with the plasma 
membrane with fluorine NMR requires that the cells remain suspended during 
data acquisition. CHO-K1 cells tend to settle quickly to the bottom of NMR tube 
because of their relatively large size (diameter ~20 µm). Settling of the cells and 
the 19F-labeled protein or fused construct attached to their surface will remove 
the sample from the NMR detection zone, degrading the accuracy of data 
acquisition. A few trials were done to solve this problem.  
A Shigemi NMR tube was used. Figure 3.5 shows a Shigemi tube loaded 
with α-synuclein in Hibernate E media (BrainBits, Springfield, IL). The main 
advantage of a Shigemi tube is that even if the cells settle, they will still be in the 
detection zone. Once cells settle, however, they are deprived of nutrients, and 
the pH can change in a short time thus decreasing cell viability. Hibernate E 
(BrainBits LLC, Springfield, IL) keeps the media at a pH that facilitates survival 
when cells are kept outside of their natural environment for a short time. 
Hibernate E was not useful for our experiment, because of the large amount of 
cells settling as shown by the low viability (<20%).    
Several devices [24], gels [25], and natural biodegradable polymers [26] 
have been used to prolong cells viability during NMR experiments. Ficoll, a 
hydrophilic polysaccharide, was used to prevent settling of Xenopus laevis 
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oocytes during NMR data acquisition [27]. To our knowledge, there are no 
reports on using Ficoll to keep mammalian cells in suspension.  
We tested the ability of Ficoll to keep CHO-K1 cells in suspension at 37 °C 
(Figure 3.6). After 3 h in the NMR tube, the cells settled in 10% (w/v) Ficoll and 
exhibited low viability. At 20% (w/v) the cells remained in suspension with a 
viability of 92%. At higher concentration, Ficoll may induce floatation of cells. We 
concluded that 20% (w/v) Ficoll is optimal for keeping CHO-K1 cells in the NMR 
detection zone.  
3.3.3 Interaction of Wild-type and Y125F α-Synucleins with Plasma 
Membrane 
19F-labeled wild-type α-synuclein was incubated with the cells as 
described in the Experimental Procedure Section. A decrease in the intensity of 
the middle peak was noted in the presence of cells (Figure 3.7 A). This decrease 
is probably caused by restricted motion of the protein region that interacts with 
plasma membrane. The middle peak represents an overlap of the resonances 
from positions 39 and 125 [17]. We used Y125F α-synuclein to determine which 
of the two resonances changed upon interaction with the cells. For this variant, 
the middle peak corresponds only to the resonance from position 39. A 
significant decrease in the resonance from position 39 was noted upon 
incubating Y125F α-synuclein with the cells, while the resonances from positions 
133 and 136 remained almost unchanged (Figure 3.7 B). No significant change 
in peaks intensity was noted when Y39F α-synuclein was used (Figure 3.9). Thus 
it appears that only the N-terminal region interacts with plasma membrane. 
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Control experiments were performed to check if the decrease noted is an 
artifact caused by experimental conditions. For instance, the decrease could be 
caused by a slight change in pH. To test this idea, we collected the data for the 
Y125F variant under the same conditions as those used for the sample 
containing the cells, but at pH ~6. No decrease in intensity was noted for the 
resonance at position 39 but there was a slight change in chemical shift (Figure 
3.8 A). Fluorine NMR has a high sensitivity to the environment [28]. We also 
tested the effect of Ficoll. We kept the Y125F variant in 20% (w/v) Ficoll in media 
for 12 h. No change in the intensities was noted between the initial sample, and 
the final sample (Figure 3.8 B). We concluded that a slight change in the pH of 
media or the presence of Ficoll would not cause a decrease in the resonance at 
position 39, and the reduction is an effect of the protein interacting with the cells. 
However, if the cells were mixed with 20% (w/v) Ficoll first and then the protein 
was added, a broadening of the middle peak was noted perhaps as a result of 
the increased viscosity of Ficoll. 
3.3.4 Interaction of CTP-α-Synuclein with the Plasma Membrane 
19F-labeled CTP-α-synuclein was used to study the early stage insertion of 
the CTP into the plasma membrane. CTP-α-synuclein has five tyrosines, one in 
the CTP at position -11, one at the position 39 in the N-terminal region of α-
synuclein, and three in the C-terminal region (Figure 3.1). Figure 3.9A shows the 
spectrum of 3FY-labeled fusion protein in F-12 media containing 20% (w/v) Ficoll 
and 10% D2O. A significant change was noted when CHO-K1 cells were added 
(Figure 3.10 B). After 1h, one resonance disappeared leaving a spectrum 
 65 
 
 
resembling that of wild-type α-synuclein (Figure 3.10 C). The decrease and 
disappearance of resonance is attributed to the interaction of the CTP in the 
fused construct with the plasma membrane. In summary, most of the fusion 
construct bound to the cells in the first hour as shown by the disappearance of 
resonance at position 39.  
Comparing the interaction of 19F-labeled α-synuclein and 19F-labeled CTP-
α-synuclein with the plasma membrane suggests a model wherein α-synuclein’s  
N-terminal region lies along the surface of the membrane. This is because only 
the region around position 39 interacts with the cells while the resonances from 
C-terminus remain unaffected suggesting that the C-terminal region is not in the 
proximity of membrane. No significant translocation of fluorescently-labeled 
protein was noted when wild-type α-synuclein was used as tested by confocal 
microscopy imaging. This observation indicates that the protein does not cross 
the plasma membrane, but rather only its N-terminus interacts with the cells.  For 
CTP-α-synuclein, a different type of binding is proposed. The CTP inserts 
perpendicular to the cellular lipid bilayer while the α-synuclein portion does not 
interact with plasma membrane after 1h of incubation, as suggested by the 
observation that the resonance at position 39 is unaffected. Perhaps some of the 
fused construct penetrates the lipid bilayer in the first hour, but the amount was 
insufficient for detection. 
We attempted to assign the Y-11 resonance in the fusion protein by using 
the 3FY-labeled Y-11F variant but the 19F resonances from the remaining 
tyrosines were not well resolved (Figure 3.11). This may be due to intra- and 
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intermolecular interactions between the positively charged CTP and N-terminus 
α-synuclein and the negatively charged α-synuclein C-terminus (Figure 3.1). To 
confirm that the peptide is interacting with plasma membrane and to verify that 
CTP-α-synuclein is translocating into the cells, we used a different approach. 
3.3.5 Translocation of CTP α-Synuclein in Cells 
Translocation of CTP-α-synuclein into mammalian cells was tested by 
incubating the fluorescently-labeled construct with cells for 20 h. Three cell lines, 
CHO-K1, HeLa, and primary culture neurons, were tested. The CTP translocated 
α-synuclein into all the cell types (Figure 3.12). As shown in the left hand column 
of Figure 3.12, CTP targeted the cargo to the cytoplasm as previously shown [5]. 
Mitochondrial staining confirmed localization of the protein to the cytoplasm with 
no fluorescence present in the nucleus. Mitochondria have a uniform distribution 
in the cytosol, surrounding the nucleus. Some co-localization of α-synuclein and 
mitochondria was noted in all three cell lines, especially in the neuronal cell line. 
This observation agrees with the findings presented in Chapter 2, and with other 
studies suggesting interaction of α-synuclein with mitochondria and lipid vesicles 
[29-33]. Control experiments using fluorescently-labeled α-synuclein under the 
same conditions showed no significant intracellular fluorescence when the same 
settings of the microscope were used. This observation indicates that α-synuclein 
does not cross the plasma membrane in the absence of CTP. No 
autofluorescence was noted for the cells used. These data support our model 
that α-synuclein N-terminus is along to the membrane surface while CTP is 
inserted in the lipid bilayer of plasma membrane.  
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3.4 Conclusion 
 Fluorine NMR, combined with fluorescence microscopy, provides 
information on the interaction and change in conformation of α-synuclein and 
CTP-α-synuclein. This study proves the utility of 19F NMR for investigating the 
interactions between proteins and plasma membrane. This technique can be a 
powerful tool for investigation of interactions and translocation of various carriers 
into the cells.  
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3.5 Figures 
 
       
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of CTP covalently attached to the N-
terminus of α-synuclein  
The red bars show the positions of tyrosines. The green bar shows the 
fluorescently-labeled position.   
N-terminus   (cationic)  C-terminus (anionic)  NAC (hydrophobic) YGR2AR6 
Alexa Fluor488 
α-Synuclein 
-11 1 
3 
39 125 133 136 
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Figure 3.2 Chromatograms and SDS-PAGE of wild-type and CTP-α-
synuclein 
Chromatograms of α-synuclein (A red, fractions 7-9) and CTP-α-synuclein (A 
dark blue, fractions 5-9) elution from an anion exchange column and SDS-PAGE 
analysis (B) of CTP-α-synuclein (lane 1),α-synuclein (lane 2), and protein 
markers (lanes 3 and 4).   
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Figure 3.3 MAL
Matrix-assisted laser desorption/ionization
type α-synuclein (top) and CTP
highlighted in red.   
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DI/MS of wild-type and CTP-α-synuclein
 mass spectroscopy analysis of wild
-α-synuclein (bottom). The CTP insertion is 
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CTP α-Synuclein
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Figure 3.
SDS-PAGE of purified, fluorescently
exclusion chromatography. 
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4 Purified CTP-α-synuclein 
-labeled V3C CTP-α-synuclein
The lanes represent the fractions eluted from 
Pure fractions 
 after size 
FPLC.  
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      Figure 3.5 NMR sample 
Shigemi tube containing 300 µL 15N-enriched α-synuclein in Hibernate E (10% 
D2O)  
 
 
 
 
 
 
 
 
 
 
Sample 
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Figure 3.6 NMR tubes containing cells suspended in Ficoll 
NMR tubes containing 6x106 CHO-K1 cells in 300 µL of F-12 media containing 
10% D2O with various (w/v) concentrations of Ficoll at 37 °C after 3h. The cells 
viability was 92%. 
  
Ficoll %  10     13     20 
NMR detection 
zone 
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Figure 3.7 19F NMR spectra of wild-type and Y125F α-synuclein 
(A) Interaction of 19F-labeled wild-type α-synuclein and (B) 19 F-labeled Y125F α-
synuclein with CHO-K1 cells in 20% (w/v) Ficoll. Red spectra were acquired in 
the absence of cells. The protein concentration was 100 µM. Residue 
assignments are shown above the spectra in panel A. 
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Figure 3.8 α-Synuclein in Ficoll - controls 
(A) Effect of pH and (B) incubation time in Ficoll on the 19F spectrum of Y125F α-
synuclein. 
α-Synuclein dissolved fresh in 20%  
Ficoll 
α-Synuclein in 20%  Ficoll for 12 h 
pH ~8 
pH ~6 
B 
A
19F Chemical Shift (ppm) 
19F Chemical Shift (ppm) 
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Figure 3.9 Interaction of 19F-labeled Y39F α-synuclein with CHO-K1 cells 
(A) protein only, (B) protein and cells. 
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Figure 3.10 Interaction of 19F-labeled CTP-α-synuclein with CHO-K1 cells 
Interaction of 19F-labeled CTP-α-synuclein with CHO-K1 cells as a function of 
time. (A) CTP-α-synuclein in media with 20% Ficoll, (B) CTP-α-synuclein and 
CHO-K1 cells in media with 20% (w/v) Ficoll, (C) CTP-α-synuclein with CHO-K1 
cells in media with 20% Ficoll incubated at 37 °C for 1 h. The protein 
concentration was 100 µM. The arrow indicates the decrease in the resonance 
from Y-11. 
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Figure 3.11 Attempted assignments of the Y-11 resonance in CTP-α-
synuclein  
The spectra were collected in 50 mM sodium phosphate buffer, pH 7.4 at 37 °C. 
Top: 3FY labeled wild-type α-synuclein; Bottom: Y-11F CTP-α-synuclein. 
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Figure 3.12 CTP mediated delivery of 
CTP mediated delivery of fluorescently
HeLa cells, and primary culture neurons. 
(green). Mito Tracker Red 
and merge of the three images.
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Chapter 4  
Progress towards In-cell NMR of α-Synuclein Translocated into 
Mammalian Cells 
  
Summary  
The goal of this project was to understand how the crowded environment 
in mammalian cells affects the structure of α-synuclein and to gain insight into the 
protein’s physiological role by using in-cell NMR. A series of delivery systems 
were used to translocate α-synuclein across the plasma membrane of higher 
eukaryotic cells. PEP-1, an amphipathic peptide, was used to form a noncovalent 
complex with α-synuclein and translocate the protein into cells. To assess 
translocation, valine 3 was modified to cysteine (V3C) by site-directed 
mutagenesis, and Alexa Fluor 488 C5-maleimide dye was used to label α-
synuclein at this site. Confocal laser microscopy and staining with Mito Tracker 
Red confirmed partial localization of α-synuclein at the mitochondrial level. α-
Synuclein uptake was quantified by comparing the fluorescence of cell lysates on 
10-20% gradient SDS-PAGE to standards. About 100 µM α-synuclein was 
present in a total of ~108 cells. A cytoplasmic transduction peptide covalently 
attached to the N-terminus of α-synuclein was also used to deliver α-synuclein. 
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This new biopolymer was also labeled, and confocal laser microscopy confirmed 
localization at mitochondrial level. Electroporation and two other proprietary 
reagents were used for delivery of α-synuclein, and translocation assessed by 
using confocal microscopy of live cells or fluorescence quantification on SDS-
PAGE. Preliminary in-cell NMR studies conducted on α-synuclein delivered with 
PEP-1 shows that the protein’s N-terminus was binding or cleaved inside of cells 
but the signal to noise ratio was very low so no firm conclusion could be drawn. 
4.1 Introduction 
In-cell NMR studies of natively disordered proteins are important because 
the size range detectable by NMR is larger for disordered proteins than it is for 
globular proteins. Also, relevant information about the intracellular behavior of 
these proteins may be revealed. The increased sensitivity arises from differences 
in global and local motions for globular and disordered proteins [1]. The 
properties of globular proteins do not change too much with experimental 
conditions but the properties of natively disordered proteins can vary  significantly 
[2].  
The first in-cell NMR study of an intrinsically disordered protein was 
reported by Dedmon et al. [3]. The protein, FlgM, regulates flagellar synthesis 
upon binding a transcription factor. The intracellular environment in E. coli 
causes the C-terminal half of FlgM to gain structure while the N-terminal half 
remains unstructured. Also, McNulty et al. used in-cell NMR to investigate the of 
α-synuclein in E. coli [4].   
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The 1H-15N NMR experiments of 15N-enriched B1 domain of streptococcal 
protein G (GB1) in nucleated higher eukaryotic cells were conducted in Xenopus 
laevis oocytes [5]. The positions of the GB1 resonances remained the same in 
oocytes and in dilute solution, but a change in cross peak intensity was noted. It 
can be concluded that the crowded environment in cells does not affect the 
structure of GB1 but the resonances of amides involved in intramolecular 
hydrogen bonds are diminished. This observation is consistent with the idea that 
more dynamic parts of the protein are less affected by the increased viscosity in 
cells.  
 The first 1H-15N in-cell NMR spectra in mammalian cells were obtained in 
HeLa cells. Ubiquitin and ubiquitin derivatives were delivered to the cytosol by 
using covalently attached cell-penetrating peptides [6]. The 1H-15N heteronuclear 
multiple quantum coherence spectra showed that the peptide was cleaved by 
cytosolic enzymes. The 1H-15N intracellular spectrum of ubiquitin after peptide 
cleavage is similar with that of the protein in dilute solution only the resonances 
are broader.  
 The detection of proteins by NMR in higher eukaryotic cells may require 
the presence of fewer molecules of protein than in bacteria. This is expected 
because the cytosol of higher eukaryotic cells has a lower apparent viscosity 
than that of bacteria [7]. 
In-cell NMR of α-synuclein in higher eukaryotic cells may provide 
information about its structure, function, and intracellular behavior. However, 
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NMR is highly insensitive. Consequently, α-synuclein needs an efficient delivery 
system to reach detectable cytosolic concentrations.  
Several types of delivery systems for protein translocation into cells have 
been developed. These systems include covalent [8-14] and non-covalent 
peptides [15-19], polymeric nanoparticles [20-22], liposomes [23, 24], 
electroporation [25, 26]. 
 For this study, a series of delivery systems was used to translocate α-
synuclein into CHO-K1 cells, HeLa cells, and neuronal cell lines. Specifically, we 
examined the peptides PEP-1 and CTP, PULSin reagent, electroporation, and 
the proprietary QQ reagent provided by Dr. Wang at Wayne State University. 
Little is known about the intracellular structure and function of intrinsically 
disordered proteins, but these proteins are involved in signal transduction and 
are associated with protein-aggregation-based diseases, including several 
neurodegenerative disorders. The purpose of this study was to understand the 
effects of intracellular macromolecular crowding in mammalian cells on 
intrinsically disordered proteins, and more specifically on α-synuclein.  
4.2 Materials and Methods 
4.2.1 Substances and Materials  
Trypsin and all tissue culture media and reagents were purchased from 
Invitrogen (Carlsbad, CA). PEP-1 was synthesized by Elim Biopharmaceuticals 
(Hayward, CA). PULSin was purchased from Polyplus-Transfection (New York, 
NY) and the electroporation reagents from Lonza Biologics Inc. (Portsmouth, 
NH). M-PER reagent was purchased from Pierce (Rockford, IL). Ampicillin, 
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streptomycin sulfate, (NH4)2SO4 were purchased from Sigma (Sigma-Aldrich, St. 
Louis, Mo). Tris(2-carboxyethyl) phosphine hydrochloride (TCEP), 
phenylmethylsulphonyl fluoride (PMSF) were obtained from Pierce (Rockford, IL). 
Dithiothreitol (DTT) and isopropyl-beta-D-thiogalactopyranoside (IPTG) were 
acquired from Fisher Scientific (Fair Lawn, NJ) and ethylenediaminetetraacetic 
acid (EDTA) from Mallinckrodt (Raleigh, NC).  
4.2.2 Site-directed Mutagenesis  
The α-YGR2AR6 synuclein mutant (CTP-α-synuclein; Figure 3.1) was 
created in two steps with a Stratagene site-directed mutagenesis kit. First, 
YGR2A was inserted at the N-terminus of the wild-type α-synuclein gene and 
then the R6 fragment was added (Chapter 3). The V3C CTP-α-synuclein 
construct was created as mentioned in Chapter 3. 
 4.2.3 Expression and Purification of α-Synuclein Variants  
α-Synuclein constructs were expressed in E. coli and purified following the 
procedure described by McNulty et al. [2] with modifications as described in 
Chapter 3.  
4.2.4 Alexa Fluor Labeling  
The V3C and V3C CTP-α-synuclein derivative were labeled with Alexa 
Fluor 488 C5-maleimide dye as described in Chapter 3. The extinction coefficient 
at 494 nm, 71,000 M-1cm-1, for Alexa Fluor 488 was used to quantify the 
fluorescently-labeled protein, and the Lowry assay was used to quantify the total 
amount of protein. Aliquots of 1 mg labeled protein were lyophilized and stored at 
– 80 °C.  
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4.2.5 Cell Culture  
The Chinese hamster ovary (CHO-K1) and human epithelial carcinoma 
(HeLa) cell lines were obtained from UNC Lineberger Cancer Center. Cells were 
seeded in 6-well plastic uncoated plates (Corning Life Sciences, Lowell, MA) at a 
density of ~2x105 cells/well in F-12 for CHO-K1 cells and Dulbecco’s modified 
Eagle’s medium, DMEM, for HeLa cells, each supplemented with 10% FBS, 
penicillin (100 units/mL), and streptomycin (100 µg/mL) at 37 °C in 5% CO2.  
Primary murine sympathetic neurons were dissected from the superior 
cervical ganglion as described by Deshmukh and Johnson [27], and seeded at 
~2x104 neurons/6-well plate coated with collagen. The neurons were kept in 
AM50 media supplemented with 10% FBS, penicillin (100 units/mL), 
streptomycin (100 µg/mL), and neuronal growth factor at 37 °C in 5% CO2. For 
fluorescence imaging, the cells were seeded using the same conditions but on 
plastic 6-well plates with glass bottoms (Corning).  
4.2.6 Carriers for α-Synuclein Translocation into Mammalian Cells 
4.2.6.1 PEP-1  
Fluorescently-labeled α-synuclein was translocated into CHO-K1, HeLa 
cells, and neurons by forming a complex with the peptide, PEP-1. The peptide 
forms ~100 nm diameter complexes with the proteins (Figure 4.1). The protein 
(100 µg)/PEP-1 complexes with molar ratios 1:40, 1:20, 1:15, and 1:10, 
respectively, were studied. The complexes were formed in 200 µL PBS and then 
diluted to 600 µL with serum free media. The mixture was incubated for 30 min at 
37 °C. The cells were then treated with the complex as presented in Figure 4.2. 
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Cells at 60-80 % confluency were overlaid with α-synuclein/PEP-1 complex and 
incubated for 30 min at 37 °C. One mL of media containing serum was added to 
each well and the cells were further incubated for 2 h. SDS-PAGE (BioRad, 
Hercules, CA) and standards of 0.10 and 0.010 mg/mL fluorescently-labeled α-
synuclein were used to quantify the intracellular concentration of α-synuclein. As 
controls, cells treated with fluorescently-labeled protein alone (no PEP-1) and 
untreated cells (to check for autofluorescence) were tested under the same 
conditions. Next, the cells were washed twice with PBS and then incubated with 
trypsin/EDTA at 37 °C for 5-10 min. The cells were collected by centrifugation 
and washed with PBS. The cells were imaged and intracellular fluorescently-
labeled protein was quantified on SDS-PAGE.  
Intracellular degradation of α-synuclein was studied. Fluorescently-labeled 
protein in complex with PEP-1 (α-synuclein to PEP-1 molar ratio of 1:10) was 
incubated with the cells for 1 h under the same conditions as described above. 
The complex was removed and the cells were washed and detached by 
trypsinization at different times Trypsinized cells were then stored at -20°C. After 
18 h the samples thawed, lysed and loaded on SDS-PAGE. Standards of 0.10 
and 0.010 mg/mL of fluorescently-labeled protein were loaded on the gel as a 
reference for α-synuclein. Attempts to determine the in-cell NMR spectrum were 
conducted in CHO-K1 cells.  
4.2.6.2 Cytoplasmic Transduction Peptide (CTP)  
For CTP-α-synuclein (Figure 3.1), 100 µg/mL fluorescently-labeled CTP or 
75 µM 19F-labeled CTP-α-synuclein were overlaid onto CHO-K1 cells. The cells 
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were incubated at 37 °C and 5% CO2 for 20 h. Confocal microscopy images were 
collected and attempts to determine the in-cell NMR spectrum of α-synuclein 
were conducted. Delivery of fluorescently-labeled CTP α-synuclein was also 
tested in HeLa cells and neurons. 
4.2.6.3 Cationic Amphiphile Molecule (PULSin) 
Samples of 4 µL of 1 mg/mL fluorescently-labeled α-synuclein were used. 
The ratios of protein to PULSin (Polyplus-Transfection, New York, NY) tested 
were 1:2, 1:3, and 1:4 (v/v). The CHO-K1 cells were incubated with the protein-
PULSin complex for 5 h. Studies in the presence and absence of the lysosomal 
proteolysis inhibitor, NH4Cl, were conducted. After washing with PBS and cell 
media, the cells were imaged and lysed using the M-PER reagent (Pierce). 
Comparative analysis of delivered protein in the presence or absence of NH4Cl 
was studied on SDS-PAGE.  
4.2.6.4 Electroporation 
Electroporation of the cells was done by using the cell line nucleofector 
kits - R for HeLa cells and T for CHO-K1 cells (Lonza Biologics Inc.). The 
AMAXA instrument used for electroporation was provided by Lonza Inc. and a 
specialist from their technical team came to try to translocate α-synuclein and 
GFP to CHO-K1 and HeLa cells. It is company policy that the instrument can be 
used only by their team members till it is purchased. Their procedure is highly 
optimized for DNA transfection but not for protein translocation into the cells. 
Cells seeded at 70-80% confluency were detached by trypsinization and 
collected by centrifugation. About 106 cells were used for each experiment. The 
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cells were mixed with 5 µL of 1 mg/mL fluorescently-labeled α-synuclein or GFP 
and with 100 µL nucleofector solution. Optimization as a function of current 
intensity and time of electroporation was tried for both cell lines and for both 
proteins. In all cases, the cells were not kept in the nucleofector solution longer 
than 15 min. The pmaxGFP gene provided by Lonza was used as a control of 
electroporation. All the cells were seeded in 6-well plates in their media 
containing serum. The samples were analyzed on the second day after 
incubation at 37 °C and 5% CO2. 
4.2.6.5 QQ Reagent 
The QQ reagent was used to translocate α-synuclein into CHO-K1, HeLa 
cells, and neurons. A mixture of 10% fluorescently-labeled α-synuclein and 15N α-
synuclein was used. The QQ reagent and the protein modification were done in 
Dr. Jianjun Wang’s laboratory at Wayne State University [28]. The cells were 
treated with the QQ modified protein at a concentration of 1 mg/mL α-synuclein. 
4.2.7 Fluorescence Image Acquisition and Quantification  
For cell imaging, four washing steps with PBS were performed and then 
the cells were imaged in their complete media using a Zeiss confocal microscope 
equipped with LSM 5 software with a 40x oil objective. In addition, the cells were 
incubated with 50 nM Mito Tracker Red CMX Ros (Invitrogen) for 15 min 
immediately before imaging. Fluorescence imaging was performed using 
multichannel detection of excitation with an argon laser (488 nm) for Alexa Fluor 
488 labeled protein and a HeNe1 laser (543 nm) for Mito Tracker Red detection. 
For intracellular protein quantification, cells were lysed using M-PER mammalian 
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protein extraction reagent following the protocol. Twenty five µL of the 
supernatant were loaded on 10-20% gradient SDS-PAGE (BioRad) for 55 min at 
200 V, and the intracellular fluorescence was quantified with a VersaDoc MP 
imager (BioRad). Two known concentrations of fluorescently-labeled α-synuclein 
were used as standards. Cells incubated under the same conditions with 
fluorescently-labeled α-synuclein (no carrier) were used as a negative control. 
Cells untreated with the peptide, protein, or the complex were lysed to test for 
autofluorescence. 
4.2.8 In-cell NMR  
In-cell NMR experiments were conducted in CHO-K1 cells. The cells were 
seeded at a density of ~106 cells in a T75 flask (Corning, Edison, NJ). The cells 
at 70-80% confluency were overlaid with the PEP-1/19F-labeled α-synuclein 
complex or with 19F-labeled CTP-α-synuclein as described in the section on 
carriers for α-synuclein delivery. For the α-synuclein/PEP-1 complex, the 
concentration of α-synuclein was adjusted to correspond to that for experiments 
performed with fluorescently-labeled protein.  
For CTP α-synuclein, a concentration of 75 mg/mL was used. After 
successive washings with PBS and cell media, the cells were trypsinized and 
resuspended in 20% Ficoll containing 10% D2O as described in Chapter 3. The 
cells were placed in a 5-mm diameter NMR tube. A sample of 90:10 (v/v) 20% 
Ficoll in cell media to D2O was used under the same conditions as a reference 
for shimming, pulse-width determination, and for determination of solvent-
saturation frequency. The 19F spectra were acquired at 37 °C as described in 
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Chapter 3. Data were processed by using MestReNova LITE (Mestrelab 
Research, Escondido, CA). NMR control experiments on the supernatant 
obtained after cell centrifugation and on the cell lysates were performed under 
the same conditions. 
4.2.9 Cell Viability  
Cell viability after each NMR experiment was tested by using the trypan 
blue exclusion assay.  
4.3 Results and Discussion  
4.3.1 Expression and Purification of α-Synuclein Variants  
All α-synuclein variants were expressed in E. coli and purified as 
described under Materials and Methods. The protein yields varied between 28 
and 60 mg of pure protein per L of culture. Several long term storage conditions 
were tested. Lyophilization followed by storage at –80 °C proved to be important 
for avoiding degradation.  
4.3.2 Alexa Fluor Labeling  
Labeling α-synuclein variants with Alexa Fluor 488 C5-maleimide dye 
allows intracellular visualization and quantification of the proteins. The labeled 
biomolecules were successfully purified from excess free dye and other 
components of the reaction mixture. The labeling efficiency varied between 70 
and 94%.   
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4.3.3 PEP-1 Mediated Delivery of α-Synuclein  
Confocal micrographs show that α-synuclein was successfully 
translocated into all the three cell lines tested – CHO-K1, HeLa, and sympathetic 
neurons - by using the amphipathic peptide PEP-1 as a carrier (Figure 4.3, 
green). Mitochondria stained with Mito Tracker Red (Invitrogen) provide 
information about colocalization of the protein at the mitochondria level and 
distribution of the protein in the cytoplasm (Figure 4.3, red). Part of the protein is 
in the cytosol while some of the α-synuclein is associated with mitochondria. 
These findings are in agreement with those of Parihar et al. [29] and Cole [30] 
who demonstrated the presence of α-synuclein in mitochondria and with the data 
presented in Chapter 2. No significant fluorescence was observed in the nucleus. 
      Quantification of the intracellular fluorescently-labeled α-synuclein 
translocated into CHO-K1 and HeLa cells (Figure 4.4) showed that the amount of 
intracellular protein increases with increasing the amount of α-synuclein in the 
complex (Figure 4.4 A-D). A protein to PEP-1 molar ratio of 1:10 was found to be 
the best of those tested for the delivery of high amounts of α-synuclein into cells. 
About 100 µM α-synuclein was present in ~2x107 cells suspended in ~600 µL of 
media with 20% Ficoll. No significant intracellular fluorescence was noted when 
only the labeled protein was incubated with CHO-K1 or HeLa cells. Also, no 
internal fluorescence was noted for either cell line when the same settings of the 
microscope were used. 
Intracellular degradation of α-synuclein translocated using PEP-1 was 
studied in CHO-K1 cells (Figure 4.5). α-Synuclein degrades inside the cells over 
time (Figure 4.5, bottom). Almost all the protein degraded after 4 h of incubation 
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at 37 °C when the cells were kept in their media. No intact protein was detected 
after 18 h but thick bands at the bottom of the gel corresponding to the free dye 
were observed. Degradation was reduced when the cells were kept in media 
containing the lysosomal proteolysis inhibitor, NH4Cl (Figure 4.5, top). This 
observation indicates that the lysosome is important for intracellular degradation 
of α-synuclein, perhaps playing a physiological role in removing α-synuclein from 
the cells or brought to lysosome during import.  
 In-cell NMR studies of wild-type 19F-labeled α-synuclein were conducted in 
CHO-K1 cells. The in-cell spectrum of 19F-labeled α-synuclein is presented in 
Figure 4.6, top. The signal to noise ratio is poor, and the spectrum of the protein 
can barely be distinguished. Three peaks of almost equal size can be seen. The 
similarity of this spectrum with that of 19F-labeled α-synuclein bound to the 
membranes suggests that the N-terminus of the protein binds to membranes 
inside the cells (Figure 3.7). The peaks are present around the same chemical 
shift as those from the 19F-labeled α-synuclein in the media containing 20% 
Ficoll. An alternative explanation is that, as 19F-labeled α-synuclein starts 
degrading inside the cells, the N-terminus region is cleaved and binds to the 
negatively charged membranes impeding the rotation of the tyrosine at the 
position 39 and consequently reducing the signal corresponding to this position. 
NMR control experiments were performed indicating that the signal is not coming 
from the protein that leaks from the cells (Figure 4.6, bottom).  
In-cell NMR experiments in the presence and absence of NH4Cl were 
conducted (Figure 4.7). The signal to noise ratio is poor because little α-synuclein 
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was translocated into the cells. However, the spectrum in the presence of 
lysosomal proteolysis inhibitor is similar with that of wild-type 19F-labeled α-
synuclein in dilute conditions. Even though the peaks are broader than those of 
the protein in 20% Ficoll or those corresponding to the protein bound to the 
plasma membrane (Figure 3.7), the middle peak corresponding to positions 39 
and 125 is larger in the presence of lysosomal inhibitor supporting the 
supposition that the N-terminus may be cleaved in the absence of NH4Cl.  
All the NMR data were collected by using the hfdiff probe. Two different 
probes were tested for their sensitivity using a small 19F molecule, 3-fluoro-
tyrosine (Figure 4.8). The HFCX probe (S/N=100.1) gives ~2 times better signal 
than the hfdiff probe (S/N=46.3). The in-cell NMR experiments were repeated on 
the HFCX probe but the results were not reproducible. Cell viability after each 
NMR experiment was ~90% for all the experiments. 
4.3.4 Delivery of α-Synuclein into Mammalian Cells by Using CTP  
The cytoplasmic transduction peptide containing the 11 amino acid 
insertion, YGR2AR6, at the N-terminus of α-synuclein (Figure 3.1) was used to 
target the protein to the cytoplasm of three cell lines – CHO-K1, HeLa, and 
primary culture neurons. The V3C CTP α-synuclein was labeled with Alexa Fluor 
488 maleimide dye with a labeling efficiency of 70-78%. Upon translocation, the 
CTP α-synuclein is cleaved by specific cytosolic enzymes and  the protein is 
released [30]. Confocal micrographs show intracellular localization of α-synuclein 
in all the three cell lines tested (Figure 4.9). Some of the protein is localized in 
the mitochondria as we noted for α-synuclein translocated by using PEP-1 
 98 
 
 
(Figure 4.3). However, no fluorescence was present in the nucleus. The CTP α-
synuclein was incubated with the cells for 20 h because CTP is efficient in 
translocating significant amounts of cargo into the cytosol only after long periods 
of incubation [30]. During this time some of the delivered protein starts to 
degrade. The SDS-PAGE gels show almost no protein present in cells.  
In-cell NMR experiments were attempted in CHO-K1 cells. Because of the 
cationic nature of the CTP, the cleaved peptide is supposed to interact with the 
negatively charged phospholipids in the intracellular membranes. Consequently, 
the peptide is not free to tumble and the resonances from the NMR active nuclei 
present in the peptide cannot interfere with the resonances from the protein [6]. 
After the incubation with 19F-labeled CTP α-synuclein, 2x107 cells were placed in 
a NMR tube in media containing 20% Ficoll and 10% D2O as described in 
Chapter 3. No signal was detected in cells or in the cell lysates perhaps because 
not enough α-synuclein was delivered into the cells. 
4.3.5 Translocation of α-Synuclein by Using PULSin 
PULSin is a commercially available reagent that contains a proprietary 
cationic amphiphile [31, 32]. It facilitates delivery of anionic proteins and 
antibodies into the cells. Different v/v ratios of 1 mg/mL fluorescently-labeled α-
synuclein and PULSin were incubated with CHO-K1 cells in the presence and 
absence of NH4Cl. Intracellular fluorescence was observed in all the cases by 
microscopic observation. The cell micrographs were not recorded by using 
confocal imaging. Instead, the cells were lysed to determine if significant 
amounts of α-synuclein were translocated into the cells. As seen in Figure 4.10, 
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fluorescently-labeled α-synuclein is present only in the cells kept in media 
containing lysosomal proteolysis inhibitor.  
My experiments using PEP-1 showed that the lysosome is important for α-
synuclein degradation. The results using PULSin confirm this conclusion.  
The in-cell NMR experiments with 19F-labeled α-synuclein were not 
attempted because an insignificant amount of intracellular fluorescence was 
noted in cells and also because of the high cost of PULSin. 
4.3.6 Electroporation 
 Translocation of α-synuclein into CHO-K1 and HeLa cells was assessed 
using electroporation. The team from Lonza assisted me with the use of the 
instrument. The advantage of electroporation is that the protein can be delivered 
to the cells and no peptide cleavage or decaging is necessary in the cytosol. This 
allows easy detection of the NMR signal in cells without interference from the 
delivery reagent. The translocation of the protein takes place through pores 
formed in the plasma membrane because of the electric current applied. The 
exposure time and intensity of the current depends on the type of cells and the 
amount of protein to be translocated. In our case, the disadvantages of 
electroporation are the large amount of α-synuclein needed and the low cell 
viability that results from applying the current. 
Fluorescently-labeled α-synuclein was translocated into CHO-K1 and 
HeLa cells and the cells were allowed to recover in their media for ~24 h after 
which they were imaged. No fluorescent SDS-PAGE band corresponding to α-
synuclein was noted after almost 24 h. Instead, the presence of various bands of 
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different intensities at the bottom of the gel indicates that the α-synuclein was 
degraded and only the free dye remained (Figure 4.11). Fluorescence was noted 
in all the cells and for all the conditions tested. As a general trend, more 
fluorescence was present but fewer cells were observed by increasing the 
current. This trend was noted on SDS-PAGE, too. The parameters and the 
programs used for translocation were optimized at Lonza, but the information 
was not disclosed. Delivery of GFP by using electroporation was tried in the 
same cell lines but the experiments were not successful perhaps because of the 
high molecular weight of GFP (~27 kDa) as compared to α-synuclein (~14 kDa). 
The vector containing the GFP gene was used as control for electroporation and 
the cells became fluorescent the second day indicating that GFP was expressed 
in the cells as a result of gene translocation. 
4.3.7 QQ Reagent as a Carrier 
QQ reagent is a proprietary mixture of components and the sample 
containing our protein of interest was prepared in Dr. Wang’s laboratory at 
Wayne State University [28]. A mixture of 10% fluorescently-labeled and 90% 
15N-enriched α-synuclein was used. The translocation of α-synuclein was tried in 
CHO-K1, HeLa, and primary culture neurons. As seen in Figure 4.12 no 
significant fluorescence is present inside the cells. Instead, most of the protein 
appears to be on top or surrounding the cells. In our case, QQ reagent is not an 
appropriate reagent for the delivery of α-synuclein to the cells. 
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4.4 Conclusion 
Protein function may be affected as a result of intracellular 
macromolecular crowding or upon binding to different cellular components. 
Understanding the intracellular factors that play a role in the protein’s behavior 
are important for studying intracellular protein-protein interactions, protein-drug 
interactions, protein diffusion and stability. α-Synuclein was successfully 
translocated into the cytoplasm of CHO-K1, HeLa, and primary culture neurons 
by using two peptides (PEP-1 and CTP) as carriers, electroporation, and the 
PULSin reagent. The amount of translocated protein increases with increasing 
protein concentration in the PEP-1/α-synuclein complex for CHO-K1 and HeLa 
cells. CTP, electroporation and PULSin successfully translocated α-synuclein into 
CHO-K1 and HeLa cells but either the protein was degraded during time or not 
enough α-synuclein was present in cells to conduct in-cell NMR experiments. 
Some of the protein is localized in the mitochondria with more mitochondrial 
localization in sympathetic neurons. In-cell NMR experiments performed on cells 
with protein translocated by using PEP-1, reveal that the protein was delivered to 
the cells but not in high enough amounts to be able to record an acceptable 
spectrum. 
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4.5 Future Directions 
Significant amounts of α-synuclein have to be delivered into the cells for 
the protein to be detected using NMR. For the PEP-1/α-synuclein complex, one 
way to improve the translocation would be to repeat the procedure up to four 
times allowing the cells to recover in their media between treatments.  
For CTP-α-synuclein, the aforementioned procedures can also improve 
protein translocation. In addition, treatment of the cells with pyrenebutyrate prior 
to their treatment with CTP should increase the α-synuclein concentration. 
Pyrenebutyrate creates pores in the plasma membranes allowing the protein to 
pass into the cytoplasm. Similar findings were reported for the translocation of 
cationic peptides [6, 33, 34]. 
Electroporation is another technique capable of delivering proteins inside 
the cells. The electroporation time and the intensity of the current are specific for 
each protein and require optimization. For that, it is more convenient to have the 
electroporator in the laboratory to be able to perform those trials. 
For all the delivery systems used, it is important to mention as a limitation 
the high cost of the reagents or peptide used necessary to conduct in-cell NMR 
experiments. High number of cells containing important quantities of translocated 
protein is needed because of the low sensitivity of NMR. 
 Another relevant aspect is studying and understanding the interactions 
and intracellular behavior of α-synuclein variants, A30P and A53T, which may 
reveal important information about Parkinson’s disease. 
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4.6 Figures  
 
 
 
  
   
 
 
 
 
Adapted from M.A. Munoz-Morris et al. [16] 
 
 
 
Figure 4.1 Schematic representation of the PEP-1/α-synuclein complex 
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Ratio 10:1 
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Adapted from: http://www.activemotif.com/documents/82.pdf 
 
 
 
 
 
 
 
Figure 4.2 Schematic representation of α-synuclein translocation into 
higher eukaryotic cells using the PEP-1 peptide as a carrier 
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Figure 4.3 Translocation of CTP-α-synuclein into cells 
Intracellular localization of α-synuclein after incubation of cells with fluorescently-
labeled α-synuclein/PEP-1 complex at 37 °C for 2 h. The cells were also 
incubated with 50 nM Mitotraker Red at 37 °C for 15 min before imaging.  
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Figure 4.4 Cell lysates after translocation of PEP-1/α-synuclein complex 
SDS-PAGE of cell lysates after translocation of fluoerescently-labeled α-
synuclein into CHO-K1 and HeLa cell lines. Lanes A, B, C, and D represent 
protein to PEP-1 molar ratios of 1:40, 1:20, 1:15, and 1:10, respectively, S1 and 
S2 are standards (0.10 and 0.010 mg/mL, respectively) fluorescently-labeled α-
synuclein, E cell lysates after translocation of fluorescently-labeled α-synuclein 
without PEP-1. F cells alone, to check for autofluorescence.  
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Figure 4.5 Intracellular degradation of 
SDS-PAGE of cell lysates 
labeled α-synuclein after incubation of CHO
presence (top) or absence (bottom) of NH
and 0.010 mg/mL, respectively
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Figure 4.6 In
CHO-K1 cells (top) and the supernatant after the experiment (bottom).
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Figure 4.7 In-cell NMR of wild-type α-synuclein with and without NH4Cl 
CHO-K1 cells without (top) and with (bottom) the lysosomal proteolysis inhibitor, 
NH4Cl. 
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Figure 4.8 The sensitivity of two NMR probes tested using 3
The HFCX (top) has better sensitivity than the hfdiff (bottom).
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Figure 4.9 Translocation of CTP-α-synuclein into cells  
Intracellular localization of α-synuclein after incubation of the cells with 
fluorescently-labeled CTP α-
 
synuclein at 37 °C for 20 h. The cells were also 
incubated with 50 nM Mitotraker Red at 37 °C for 15 min before imaging.  
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Figure 4.10 SDS-PAGE of cell lysates containing PULS
 
SDS-PAGE of CHO-K1 cells after incubation 
with PULSin for 5h at 37 °C. For lanes 1, 2, and 3 
reagent were used: 8, 12, and 16 
lanes “a” no NH4Cl was used and for lanes “b” 25 mM NH
cells media. 
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Figure 4.11 SDS-PAGE of cell lysates after translocation of 
CHO
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1-6 represents different conditions for electroporation time and intensity. 
experimental conditions were not disclosed by Lonza, the company that provided 
as the instrument. 
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Figure 4.12 Distribution of QQ modified α-synuclein upon interaction with 
the cells 
Distribution of α-synuclein after incubation of the cells with QQ modified protein 
at 37 °C for 3 h. The sample contains 10% fluorescently-labeled α-synuclein and 
90% 15N-enriched wild-type α-synuclein. The cells were also incubated with 50 
nM Mitotraker Red at 37 °C for 15 min before imaging. DIC - differential 
interference contrast microscopy. 
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